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ABSTRACT
Human cytomegalovirus (HCMV) is a betaherpesvirus that infects up to 80% of the population
worldwide, and establishes latency in monocytes and bone marrow cells. Reactivated HCMV
can become an opportunistic pathogen in individuals who are immunocompromised, such as
those with acquired immunodeficiency syndrome (AIDS). HCMV infection of AIDS patients
causes a sight‐threatening retinitis that leads to vision loss and blindness in up to 46% of this
population without antiretroviral treatment. Because untreated HIV‐infected individuals exhibit
the loss of cell‐mediated immunity and alterations in CD4+ T‐helper (Th) cell cytokines, includ‐
ing elevation of interleukin‐4 (IL‐4), IL‐10, and IL‐17, we sought to test the hypothesis that these
cytokines play key roles in governing the susceptibility to AIDS‐related HCMV retinitis. This hy‐
pothesis was tested utilizing a clinically relevant mouse model of experimental murine cy‐
tomegalovirus (MCMV) retinitis that occurs in C57BL/6 mice immunosuppressed by mouse ret‐
roviruses (MAIDS). Studies revealed that MAIDS progression was associated with increased lev‐

els of IL‐4 and IL‐10, cytokines whose production has been associated with diminished CD8+ T‐
cell‐mediated immunity during HIV infection. However, MCMV–infected eyes of retinitis‐
susceptible IL‐4‐/‐ or IL‐10‐/‐ MAIDS mice exhibited frequency and severity of retinitis and viral
titers equivalent to MCMV‐infected eyes of wild‐type MAIDS animals. These studies indicated
that neither IL‐4 nor IL‐10 alone play key roles in increased susceptibility to MCMV retinitis. In
comparison, IL‐17, an inflammatory cytokine associated with the ocular autoimmune disease
uveitis, was systemically increased during the progression of MAIDS, but MCMV‐infected eyes
of retinitis‐susceptible MAIDS mice exhibited a significant reduction in IL‐17. These findings
suggested that IL‐17 plays no direct role in the pathogenesis of experimental MCMV retinitis.
However, these results also suggested the remarkable possibility that MCMV downregulates IL‐
17 production, a hypothesis supported by the observation that systemic MCMV infection of
healthy and MAIDS mice resulted in the downregulation of IL‐17. Mechanistic studies revealed
that knockdown of IL‐10 resulted in a partial recovery IL‐17 levels during MCMV infection. We
conclude that MCMV‐induced IL‐17 downregulation occurs via the stimulation of IL‐10 and the
suppressor of cytokine signaling (SOCS)‐3. Taken together, our results add new information to
the immunobiology of HCMV and to our basic understanding of the pathogenesis of AIDS‐
related HCMV retinitis.
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1
1.1

INTRODUCTION
Classification and Clinical Significance of Herpesviruses
Herpesviruses are widely distributed in nature, with at least one herpesvirus found within

a majority of animal species. The family Herpesviridae is characterized as viruses with large
double‐stranded DNA genomes [120‐240 kilobase pairs (kbp)], viruses that replicate and as‐
semble within the nucleus, and viruses that establish life‐long latent infection (Arvin et al.,
2007; Knipe and Howley, 2007; Wildy et al., 1960). The Herpesviridae family is divided into
three subfamilies: Alphaherpesvirinae, Gammaherpesvirinae, and Betaherpesvirinae (Arvin et
al., 2007; Knipe and Howley, 2007; Matthews, 1979; Melnick, 1982; Roizman et al., 1981). The
Alphaherpesvirinae subfamily is neurotropic in nature and includes herpes simplex virus type‐1
(HSV‐1), herpes simplex virus type‐2 (HSV‐2), and varicella‐zoster virus (VZV) (Davison et al.,
2009; Enquist et al., 1998; Evans and Melnick, 1949; Knipe and Howley, 2007; Schneweis and
Brandis, 1961; Smith and Melnick, 1962; Weller et al., 1958). Alphaherpesviruses initially infect
epithelial cells via direct contact, and the virus quickly disseminates to sensory ganglia where
latent infection is established (Cohrs and Gilden, 2011; Cohrs and Gilden, 2001; Knipe and
Howley, 2007; Melnick, 1982). Viral reactivation is triggered through stress and/or other envi‐
ronmental factors (Cohrs and Gilden, 2011; Cohrs and Gilden, 2001; Knipe and Howley, 2007).
Epstein‐Barr virus (EBV) and Human herpesvirus 8 [(HHV‐8), also known as Kaposi’s sarcoma‐
associated herpesvirus (KSHV)] are found within the lymphotropic Gammaherpesvirinae sub‐
family (Antman and Chang, 2000; Burkitt and O'Conor, 1961; Epstein et al., 1964). Like alpha‐
herpesviruses, gammaherpesviruses initially infect epithelial cells, but gammaherpesviruses dis‐

2

seminate through and establish latency in B cells (Antman and Chang, 2000; Davison et al.,
2009; Henderson et al., 1977; Knipe and Howley, 2007; Rivas et al., 2001). Lastly, viruses found
within the subfamily Betaherpesvirinae are lymphotropic in nature and include Human
herpesvirus 6 (HHV‐6), Human herpesvirus 7 (HHV‐7), and human cytomegalovirus (HCMV)
(Caselli and Di Luca, 2007; Davison et al., 2009; Frenkel et al., 1990; Knipe and Howley, 2007;
Salahuddin et al., 1986). Betaherpesviruses initially infect epithelial cells found within mucosal
surfaces and disseminate via leukocytes where latency is established. HCMV‐infected cells be‐
come enlarged and display a pathology known as cytomegalia (Goodpasture, 1921; Knipe and
Howley, 2007; Melnick, 1982).
HCMV was first noted in the 1900’s to cause an owl‐eye pathology in the salivary gland,
pancreas, liver, lungs, and kidneys of infants at autopsy (Farber and Wolbach, 1932;
Goodpasture, 1921; Ribbert, 1904). This pathology was later coined cytomegalic inclusion dis‐
ease (CID) (Knipe and Howley, 2007; Wyatt et al., 1950). HCMV was first isolated from human
salivary glands in 1955 by Margaret Smith (Smith, 1956); two other independent laboratories
soon followed suit with the isolation of HCMV as well (Craig et al., 1957; Rowe et al., 1956).
Prior to the isolation of HCMV, Smith also isolated the mouse‐specific virus, murine cytomega‐
lovirus (MCMV), from mouse salivary glands (Knipe and Howley, 2007; Smith, 1954). While
CMVs infect numerous animal species, and while CMVs share genomic structure and organiza‐
tion, they diverge from one another based upon their host genes and are therefore species‐
specific (Davison et al., 2003; Hudson, 1979; Jordan, 1983; Knipe and Howley, 2007; Reddehase,
2006). HCMV infects up to 80% of the population worldwide (Knipe and Howley, 2007;
Reddehase, 2006). HCMV infection is typically asymptomatic, and the virus establishes a life‐
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long infection in monocytes and bone marrow cells (Knipe and Howley, 2007; Mendelson et al.,
1996; Reddehase, 2006; Sinclair, 2008; Slobedman and Mocarski, 1999; Taylor‐Wiedeman et al.,
1991). HCMV can become pathogenic, however, in individuals who are immunocompromised.
Additionally, HCMV is able to cross the placenta during pregnancy to cause disease in develop‐
ing neonates known as congenital cytomegalovirus infection (Crough and Khanna, 2009; Knipe
and Howley, 2007; Reddehase, 2006).
1.2

Human Cytomegalovirus Genome and Virion Structure
The HCMV genome consists of linear double‐stranded DNA. The genome is divided into

two regions: the unique long (UL) region and the unique short (US) region (Kilpatrick and
Huang, 1977; Spaete and Mocarski, 1985a; Weststrate et al., 1980). The regions’ ends are
flanked by terminal repeats, and the regions are divided by a series of internal repeats (Figure
1.1) (Knipe and Howley, 2007; Spaete and Mocarski, 1985a; Weststrate et al., 1980). The ge‐
nome of approximately 235 kbp consists of 200 open reading frames (ORFs) that encode ap‐
proximately 70 proteins (Crough and Khanna, 2009; Davison et al., 2003; Dunn et al., 2003b;
Reddehase, 2006).
HCMV virions are approximately 250 nm in diameter, spherical, and enveloped (Wildy et
al., 1960; Wright et al., 1964). The virion envelope surrounds the viral tegument proteins and
the viral DNA‐containing nucleocapsid. The tegument consists of a majority of the virion’s pro‐
teins, making up 40% of the virion’s mass (Kalejta, 2008; Knipe and Howley, 2007). In addition,
the tegument area houses both viral and host cell RNA (Bresnahan and Shenk, 2000; Greijer et
al., 2000; Knipe and Howley, 2007; Terhune et al., 2004). Viral tegument proteins have a wide
array of functions during HCMV infection including mediating virion delivery to the host cell nu‐
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cleus, activating immediate early (IE) gene expression, and evading the host cell immune re‐
sponse (Davison and Bhella, 2007; Kalejta, 2008; Miller‐Kittrell and Sparer, 2009). The 125‐nm
icosahedral nucleocapsid, which houses the viral DNA, is embedded in the tegument and is
composed of 5 proteins: major capsid protein (MCP), minor capsid protein (TRI1), minor capsid
protein binding protein (TRI2), smallest capsid protein (SCP), and the portal protein (PORT)
(Butcher et al., 1998; Chee et al., 1989; Dittmer and Bogner, 2005; Gibson et al., 1996; Irmiere
and Gibson, 1985; Knipe and Howley, 2007).

Figure 1.1. Schematic representation of HCMV genome. The HCMV genome is divided into two
regions of sequences, the unique long (UL) and unique short (US) sequence regions. The UL and
US are flanked by terminal repeats: terminal repeat long (TRL) and terminal repeat short (TRS).
The UL and US are divided by a series of internal repeats: internal repeat long (IRL) and internal
repeat short (IRS). Adapted from (Kotenko et al., 2000).
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1.3

Cytomegalovirus Replication Cycle
HCMV is able to infect numerous cell types including epithelial cells, endothelial cells, fi‐

broblasts, myeloid cells, and retinal pigment epithelial (RPE) cells (Bodaghi et al., 1999; Knipe
and Howley, 2007; Miceli et al., 1989; Reddehase, 2006; Sinzger, 2008). The replication and as‐
sembly of HCMV occurs within the nucleus of the host cell (Figure 1.2). HCMV genes are tran‐
scribed in a regulated cascade beginning with immediate early (IE, α) genes, followed by de‐
layed‐early or early (DE or E, β) genes, and lastly late (L, γ) genes (Reddehase, 2006; Stinski,
1978). Entry of the virion into the cell is mediated through the interactions of glycoprotein B
(gB), the glycoprotein H (gH): glycoprotein L (gL) complex, and the glycoprotein M (gM): glyco‐
protein N (gN) complex with heparan sulfate and/or other unidentified receptor(s) on the host
cell surface (Carlson et al., 1997; Huber and Compton, 1997; Kari and Gehrz, 1993; Knipe and
Howley, 2007; Mach et al., 2000; Mach et al., 2005; Reddehase, 2006). Additionally, HCMV has
been noted to enter endothelial cells through fusion with endocytic vesicles (Bodaghi et al.,
1999; Knipe and Howley, 2007; Sinzger, 2008). Once in the cytoplasm, microtubules assist with
the transport of the HCMV nucleocapsid to the host cell nucleus (Knipe and Howley, 2007;
Ogawa‐Goto et al., 2003). The viral DNA and viral tegument proteins are released into the nu‐
cleus. The expression of IE genes is initiated through viral tegument proteins phosphoprotein‐
71 (pp71) and UL35 (Knipe and Howley, 2007; Liu and Stinski, 1992; Schierling et al., 2005;
Spaete and Mocarski, 1985b; Stinski and Roehr, 1985). IE gene transcription, which occurs
within 2‐4 hours after infection, results in the production of viral regulatory proteins that lead
to the activation of DE or E genes (Knipe and Howley, 2007; Vancikova and Dvorak, 2001). DE
genes encode for viral DNA replication machinery and proteins necessary for capsid maturation
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(Knipe and Howley, 2007; Vancikova and Dvorak, 2001). DE gene products initiate L gene ex‐
pression approximately 36 to 48 hours post infection; L genes encode for the structural proteins
of the virion (Knipe and Howley, 2007; Vancikova and Dvorak, 2001). Accumulation of L‐gene
protein products within the host cell nucleus results in capsid assembly and viral DNA encapsi‐
dation (Knipe and Howley, 2007). The tegument proteins UL50 and UL53, as well as non‐
structural viral proteins, assist with the egress of the nucleocapsid from the nucleus; this is a
two‐step process, wherein the nucleocapsid buds through the inner nuclear membrane and
gains an envelope (Knipe and Howley, 2007). The enveloped nucleocapsid then loses its enve‐
lope as it is released from the outer nuclear membrane (Knipe and Howley, 2007). The viral nu‐
cleocapsid is then re‐enveloped in the cytoplasm at the endoplasmic reticulum golgi intermedi‐
ate compartment (ERGIC) (Knipe and Howley, 2007). These mature virions are transported to
the cell surface and exocytosed (Knipe and Howley, 2007).
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Figure 1.2. Human Cytomegalovirus replication cycle. (A) Virion attachment, entry and un‐
coating of viral nucleocapsid. (B) Transport of viral nucleocapsid to the nucleus via microtu‐
bules and release of viral DNA and tegument proteins into nucleus. (C) DNA replication, tran‐
scription, and translation of viral proteins under cascade regulation: IE, DE, and L genes. (D)
Capsid protein assembly. (E) Viral DNA encapsidation. (F) Nuclear egress of the viral nucleo‐
capsid. (G) Secondary envelopment at endoplasmic reticulum golgi intermediate compartment
(ERGIC). (H) Release of viral progeny. ER, endoplasmic reticulum, and GB, golgi body. Based on
(Knipe and Howley, 2007; Mocarski Jr, 2007).
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1.4

HCMV Clinical Disease
HCMV is transmitted through bodily secretions including urine, saliva, and breast milk

(Arvin et al., 2007; Britt, 2008; Crough and Khanna, 2009; Knipe and Howley, 2007; Vancikova
and Dvorak, 2001). Primary infection typically occurs in young children in the daycare setting
but can also occur in adolescents and adults (Britt, 2008; Knipe and Howley, 2007; Pass, 1985;
Staras et al., 2008; Vancikova and Dvorak, 2001). Fifty to 90% of adults are seropositive for
HCMV (Britt, 2008; Gandhi and Khanna, 2004; Staras et al., 2006; Vancikova and Dvorak, 2001).
Similar to other herpesviruses, HCMV persists in the host for life (Gandhi and Khanna, 2004;
Knipe and Howley, 2007; Slobedman and Mocarski, 1999; Vancikova and Dvorak, 2001). Fol‐
lowing primary infection, HCMV becomes latent in monocytes and bone marrow cells (Knipe
and Howley, 2007; Mendelson et al., 1996; Slobedman and Mocarski, 1999; Taylor‐Wiedeman
et al., 1991; Vancikova and Dvorak, 2001).

1.4.1 HCMV Infection of the Immunocompetent
In the immunocompetent host, acute infection is typically asymptomatic and self‐
limited. Though rare, symptoms in the immunocompetent include fever, fatigue, adenopathy,
and splenomegaly, the compilation of these symptoms being HCMV infectious mononucleosis
(heterophile antibody negative) (Britt, 2008; Klemola, 1973; Klemola and Kaariainen, 1965;
Reddehase, 2006). HCMV‐related symptoms are more common and more severe in the im‐
munocompromised due to high, uncontrolled HCMV replication (Crough and Khanna, 2009;
Kano and Shiohara, 2000; Reddehase, 2006; Rowshani et al., 2005). Additionally, immunocom‐
petent individuals that receive blood transfusions can develop HCMV infectious mononucleosis
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(heterophile antibody negative) (Lang, 1972; Monif et al., 1976; Vancikova and Dvorak, 2001).
The risk for developing HCMV mononucleosis is approximately 3%; this risk increases with the
number of blood units transfused and whether the individual receiving blood is HCMV sero‐
negative (Armstrong et al., 1976; Kane et al., 1975; Vancikova and Dvorak, 2001). Symptoms
that present in immunocompetent patients during HCMV infection typically resolve within 1‐4
weeks without treatment (Knipe and Howley, 2007; Vancikova and Dvorak, 2001). However,
chronic HCMV infection in the immunocompetent population has been linked to atherosclerotic
coronary artery disease, coronary restenosis, malignant gliomas, and inflammatory bowel dis‐
ease (Adam et al., 1997; Cobbs et al., 2002; Melnick et al., 1996; Rahbar et al., 2003;
Reddehase, 2006; Speir et al., 1994; Streblow et al., 2008). In addition, chronic HCMV infection
has recently been established as a co‐factor in age‐related macular degeneration (Cousins et al.,
2012).

1.4.2 Congenital and Perinatal HCMV Infection
HCMV is able to cross the placenta and cause congenital abnormalities in the auditory
and visual organs of a growing fetus (Arvin et al., 2007; Knipe and Howley, 2007; Malm and
Engman, 2007; Stagno et al., 1982). In developing countries, HCMV infection is the leading
cause of congenital cytomegalovirus disease, with primary HCMV infection occurring in 2% of
all pregnancies (Britt, 2008; Malm and Engman, 2007; Pass et al., 2006; Vancikova and Dvorak,
2001). The transmission rate from mother to fetus after primary infection is 40% (Britt, 2008;
Malm and Engman, 2007; Vancikova and Dvorak, 2001). If primary infection of the mother oc‐
curs prior to the second trimester, the sequelae are much more severe than if primary infection
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of the mother occurs during the third trimester (Pass et al., 2006; Vancikova and Dvorak, 2001).
At birth, 7‐10% of these infected neonates exhibit symptoms such as pneumonitis, liver disease,
encephalitis, and clotting disorders (Malm and Engman, 2007; Vancikova and Dvorak, 2001). Of
the neonates that survive, approximately 90% will have sensorineural hearing loss (Fowler and
Boppana, 2006; Fowler et al., 1992; Vancikova and Dvorak, 2001).
Because HCMV can be transmitted through cervical secretions as well as through breast
milk, it is possible for a healthy infant to become infected if the mother is HCMV‐infected
(Hayes et al., 1972; Reynolds et al., 1973). Perinatal infection that occurs in infants is typically
asymptomatic and self‐limited; however, symptoms that can occur include lymphadenopathy,
pneumonitis, and hepatitis (Granstrom and Leinikki, 1978; Leinikki et al., 1978; Vancikova and
Dvorak, 2001; Whitley et al., 1976). Depending on the severity of symptoms, treatment of peri‐
natal infection includes administration of the antiviral ganciclovir (Nigro et al., 1997).

1.4.3

HCMV Infection of the Immunocompromised
When cell‐mediated immunity is suppressed, as seen in solid‐organ transplant recipients,

bone‐marrow transplant patients, and in human immunodeficiency virus (HIV)/acquired im‐
mune deficiency syndrome (AIDS) patients, persistent HCMV infection can lead to disease de‐
velopment due to the inability of CD4+ and CD8+ T cells to control viral replication and dissemi‐
nation (Reddehase, 2000; Reddehase et al., 1985; Riddell et al., 1992; Steffens et al., 1998). The
immunocompromised population, especially solid‐organ transplant and bone‐marrow trans‐
plant patients, is at risk for developing colitis and pneumonitis as a result of HCMV infection
(Boeckh et al., 2003; Britt, 2008; Reddehase, 2006; Rowshani et al., 2005; Vancikova and
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Dvorak, 2001). Less than 1% of allograft recipients experience HCMV infection of ocular struc‐
tures (Britt, 2008). HCMV infection of the donor or of the transplant organ can contribute to
organ rejection in transplant patients due to the reactivation of latent virus and ultimately un‐
controlled virus replication in the transplanted organ (Britt, 2008; Cainelli and Vento, 2002;
Grattan et al., 1989; Lopez et al., 1974; Rubin, 1989; Vancikova and Dvorak, 2001). In addition,
HCMV‐infected donor organs have been shown to express high levels of cellular adhesion
molecules, leading to inflammatory cell infiltration and damage to the donor tissues (Cainelli
and Vento, 2002; Steinhoff et al., 1996; Waldman and Knight, 1996). In contrast to allograft re‐
cipients, HCMV infection of late‐stage HIV/AIDS patients who are not on antiretroviral therapy
(ART) frequently causes a sight‐threatening retinal necrosis in addition to gastrointestinal dis‐
eases and neurological sequelae (Britt, 2008; Dix and Cousins, 2004a; Reddehase, 2006;
Vancikova and Dvorak, 2001); however, HCMV retinitis does not appear in AIDS patients until
CD4+ T cell counts fall below 50 cells/mm3 of blood, although late‐stage HIV patients become
susceptible to other opportunistic infections when CD4+ T cell counts fall below 200 cells/mm3
of blood (AIDS) (Gerard et al., 1997; Palella et al., 1998; Salmon‐Ceron et al., 2000).

1.5

The Anatomy of the Eye
The eye is divided into two segments: the anterior and posterior segments (Figure 1.3)

(Cousins, 1997; Kiel, 2010; Kolb, 1995a; Newell, 1992). The sclera, comprised of connective tis‐
sue, encompasses the outer portion of the eye to provide integrity to the visual organ (Kolb,
1995a; Newell, 1992). The anterior segment consists of the ocular components necessary for
focusing light onto the neurosensory retina: the crystalline lens and the cornea (Kiel, 2010;
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Kolb, 1995a). In addition, the anterior segment contains the conjunctiva, iris, pupil, ciliary body,
aqueous humor, and anterior uvea (Cousins, 1997; Kolb, 1995a). The conjunctiva is comprised
of stratified‐squamous epithelium that is interspersed with goblet cells and functions to secrete
mucins that comprise the mucus of the tear film that helps to protect the ocular surface of the
eye (Gipson, 2007; Inatomi et al., 1996). The pupil is the portion of the eye that allows light to
enter, and the colored iris acts to control the size of the pupil, allowing more or less light to en‐
ter depending upon external conditions (Kardon, 1995; Kolb, 1995a; Wilhelm, 2008). The
aqueous humor, a fluid that is produced by the non‐pigmented epithelial cells of the ciliary
body, bathes the crystalline lens and helps to maintain proper ocular pressure; the aqueous
humor also contains growth factors and other nutrients (Brubaker, 1991; Chowdhury et al.,
2010; Cousins, 1997; To et al., 2002). The uvea, located between the sclera and the retina, is
the pigmented vascular portion of the eye (Caspi, 2010; Commodaro et al., 2011). The anterior
uvea is comprised of the iris and the ciliary body, while the posterior uvea consists of the retinal
choroid (Caspi, 2010; Commodaro et al., 2011).
The posterior segment consists of the vitreous cavity, the neurosensory retina, the retinal
pigment epithelium (RPE), and the choroid (posterior uvea) (Cousins, 1997; Kolb, 1995a). The
vitreous cavity comprises a majority of the posterior segment of the eye and is filled with a gel‐
like substance that is composed of hylauronic acid, collagen, water, proteins, and regulatory
cytokines (Bishop, 2000; Scott, 1992). The neurosensory retina, the area of light processing,
contains rods and cones (photoreceptors) as well as ganglion cells, bipolar cells, horizontal cells,
amacrine cells, microglia and Müller cells (Dowling, 1987; Kolb, 1995b). Cones are concen‐
trated in the foveal area of retina, where light is received, while rods dominate the remainder
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of the retina with cones interspersed (Brown and Wald, 1964; Kolb, 1995c; Marks et al., 1964).
Rod and cone cells are attached to the cells of the RPE. The RPE functions to absorb light, regu‐
late the transport of metabolites in and out of the neurosensory retina, phagocytose damaged
photoreceptor segments, and secrete cytokines such as transforming growth factor beta (TGF‐
β) (Strauss, 1995). Horizontal cells and amacrine cells are interneurons that mediate signaling
between the photoreceptors and the retinal bipolar cells (Boycott, 1988; Boycott and Kolb,
1973; Gallego, 1971; Kolb, 1995b; Poche and Reese, 2009). Signals received by the bipolar cells
are transmitted to the ganglion cells of the retina (Kolb, 1995b; Mariani, 1982). Both microglia
and Muller cells work to maintain homeostasis of the neurosensory retina (Bringmann et al.,
2006; Chen et al., 2002). Microglia are widely distributed throughout the neurosensory retina,
and are located within the outer and inner plexiform layers, the ganglion cell layer, and in the
nerve fiber layer (Boycott and Hopkins, 1981; Chen et al., 2002). Microglia act as both antigen
presenting cells (APCs) as well as phagocytic cells when activated during infection and/or retinal
damage (Chen et al., 2002). Müller cells span the entire thickness of the retina from the gan‐
glion cell layer to the retinal blood vessels; hence, Müller cells possess numerous ion channels
and transmembrane transporters that enable them to maintain retinal glucose metabolism,
regulate blood flow within the retina, and maintain water and ion balance (Bringmann et al.,
2006). In addition, in times of retinal injury and/or infection, Müller cells function as immuno‐
modulators by releasing proinflammatory cytokines as well as phagocytosing foreign sub‐
stances and damaged retinal cells (Bringmann et al., 2006). The actions of Müller cells during
infection and/or retinal assault involve the cooperation of retinal microglia, ultimately resulting
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in the alteration of retinal blood flow, which allows for the infiltration of leukocytes into the
retina (Bringmann et al., 2006).
The eye is supplied by two vasculatures. The first vasculature originates from the oph‐
thalmic artery, which branches into the central retinal artery and enters the eye through the
optic nerve (Lang and Kageyama, 1990; Raviola, 1977). This artery then branches to supply
blood to the neurosensory retina (Kolb, 1995d; Newell, 1992). The second blood supply origi‐
nates from orbital arteries that penetrate the sclera to provide blood to the anterior segment,
the uvea, the RPE, and the outer retina (Kur et al., 2012; Morrison et al., 1996; Raviola, 1977).
Divisions of this vasculature supply blood to the choroidal vessels and ciliary body (Kur et al.,
2012; Morrison et al., 1996). The lens and cornea are avascular during health; however, lacri‐
mal glands located in the corner of each eye secrete tears that supply nutrients and protection
to these structures (Cousins, 1997).
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Figure 1.3. Structure of the eye and neurosensory retina. The eye is divided into two seg‐
ments, the anterior and posterior segments. The anterior segment consists of the cornea and
crystalline lens, structures necessary for receiving and focusing light onto the posterior segment
of the eye. The posterior segment receives light at the central point of the retina, the fovea,
and is then processed by the cells of the neurosensory retina (photoreceptors: rods and cones).
Enlarged sections depict the cells and divisions of the neurosensory retina. (Caspi, 2010; Kolb,
1995d)
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1.6

Ocular Immune Privilege
The eye is a site of immune privilege similar to the central nervous system (CNS) in that if

foreign tissue were transplanted into the cornea, anterior chamber, the vitreous cavity, or the
subretinal space, the tissue would survive indefinitely, whereas if the same foreign tissue were
transplanted into another area of the body, it would be rejected by the recipient (Hazlett and
Hendricks, 2010; Kaplan and Streilein, 1977; Medawar, 1948; Niederkorn, 1990; Streilein,
2003b). The eye is compartmentalized in a similar fashion to the blood‐brain barrier of the cen‐
tral nervous system and is called the blood‐retinal barrier (Ashton and Cunha‐Vaz, 1965; Cunha‐
Vaz, 1979; Streilein, 2003b). In the posterior segment, the RPE and the retinal endothelial cells
are non‐fenestrated and have tight junctions (Shakib and Cunha‐Vaz, 1966; Shiose and Oguri,
1969; Smith and Rudt, 1975). These two cell types physically regulate molecules entering and
exiting the retina; for example, dye delivered to the vasculature is excluded from this portion of
the eye that possesses non‐fenestrated cells with tight junctions (Bellhorn, 1980, 1981; Cousins,
1997).
The blood‐retinal barrier differs between the neurosensory retina and the uveal tract.
While the passage of macromolecules into the retinal vasculature is tightly regulated, molecules
freely pass through the barrier in the uveal tract via a concentration gradient (Cunha‐Vaz, 1979;
Cunha‐Vaz et al., 1966; Raviola, 1977). Thus, the uveal tract typically contains numerous leuko‐
cytes including macrophages and dendritic cells (Bellhorn, 1980, 1981; Cousins, 1997). The bar‐
rier of the ciliary body is regulated similarly to the retinal vasculature so not to permit free flow
of molecules into the aqueous humor (Cunha‐Vaz, 1979; Shiose and Oguri, 1969; Smith, 1971).
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However, the blood‐retinal barrier is not absolute and when disrupted, unchecked immune ef‐
fector cells can enter to cause tissue destruction, vision loss, and even blindness.
In addition to a physical barrier, both the aqueous humor and the cells of the neurosen‐
sory retina produce a number of immunoregulatory molecules, including TGF‐β2, vasoactive
intestinal peptide (VIP), somatostatin (SOM), and alpha‐melanocyte stimulating hormone (α‐
MSH) that inhibit T cell activation in order to prevent extensive inflammation and ultimately
harm to the visual organ (Streilein, 2003b; Taylor, 2009; Taylor and Lee, 2010; Taylor and Yee,
2003). A similar suppression of T cell activation also occurs when antigens are introduced into
the anterior chamber. Anterior chamber‐associated immune deviation (ACAID) occurs when
macrophages (Lin et al., 2005; Wilbanks and Streilein, 1992a, b) within the anterior chamber of
the eye process foreign antigens and/or alloantigens, migrate from the eye through the blood
to the spleen, and initiate the production of suppressor T cells through the interaction with
splenic B cells (D'Orazio and Niederkorn, 1998; Kaplan and Streilein, 1977; Streilein, 2003b).
The resulting immune response leads to the suppression of the T‐helper cell responses, includ‐
ing delayed‐type hypersensitivity (DTH), to the eye‐derived antigen (Streilein, 2003a, b). This
non‐inflammatory response provides the eye another line of defense against damaging inflam‐
matory insults.

1.7

AIDS‐related HCMV Retinitis
HIV/AIDS infection is characterized by the progressive loss of cell‐mediated immunity.

CD4+ T cells are the targets of HIV; therefore, HIV‐infected patients exhibit a gradual loss of
CD4+ T cells numbers and function in both the blood and mucosal sites of the body (Williams
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and Burdo, 2009). While innate immune cells including macrophages, neutrophils, and natural
killer cells, as well as adaptive immune CD8+ T cells, remain intact during HIV infection
(Pantaleo et al., 1993; Poli et al., 1993; Williams and Burdo, 2009), the alteration of CD4+ T‐
helper cell signaling from a type 1 response to a type 2 response ultimately leads to the loss of
cellular immunity. When CD4+ T cell numbers fall below 200 cells/mm3 of blood, HIV‐infected
individuals become susceptible to a number of opportunistic infections, however, AIDS‐related
HCMV retinitis does not appear in this population until CD4+ T cell counts fall below 50
cells/mm3 of blood (Dix and Cousins, 2004a; Gerard et al., 1997; Holland, 2008; Palella et al.,
1998; Salmon‐Ceron et al., 2000).
Among these is the slowly progressive retinal disease AIDS‐related HCMV retinitis. First
noted in the early 1980’s to be affiliated with late‐stage HIV infection, AIDS‐related HCMV
retinitis caused vision loss and blindness in up to 46% of HIV/AIDS patients prior to the advent
of antiretroviral therapy (ART) (Dix and Cousins, 2004a; Holland, 2008). While ART has signifi‐
cantly reduced the number AIDS‐related HCMV retinitis cases in the United States, incidence in
the HIV/AIDS population remains high in developing countries such as Thailand and Africa
where these drugs are not readily available (Heiden et al., 2007; Stewart, 2010).
HCMV retinitis is characterized by a progressive retinal necrosis, hemorrhage, viral inclu‐
sions, and cytomegalic cells (Dix and Cousins, 2004a). HCMV retinitis can occur in one or both
eyes of the HIV/AIDS patient. HCMV disseminates through hematogenous spread of infected
monocytes that enter the retinal vasculature to become activated macrophages (Dix and
Cousins, 2004a).
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1.8

MAIDS Animal Model of MCMV Retinitis
Murine AIDS (MAIDS) infection in C57BL/6 mice results in progressive changes in immune

cell phenotype and function that closely resembles HIV/AIDS (Dix and Cousins, 2004a) (Table
1.1). MAIDS is caused by a mixture of mouse retroviruses collectively known as LP‐BM5 (Mosier
et al., 1985). The LP‐BM5 mixture is comprised of a non‐pathogenic helper virus that is replica‐
tion‐competent and a pathogenic virus that is replication‐deficient (Chattopadhyay et al., 1991;
Morse et al., 1995). The gag region products p15 and p12 of the defective, pathogenic virus
have been shown to be essential to induce MAIDS in C57BL/6 mice (Kubo et al., 1994). The gag
products of this region are expressed on B cells and act as a superantigen, which results in ex‐
tensive T cell activation (Hugin et al., 1991) and perhaps diminishes the ability of T cells to re‐
spond to other pathogens as MAIDS infection progresses. While the primary targets of LP‐BM5
infection are B cells, the retrovirus mixture is able to infect both T cells and macrophages
(Kanagawa et al., 1994; Kim et al., 1994). In addition, mice devoid of mature B cells or that lack
CD4+ T cells do not develop MAIDS (Kim et al., 1994; Yetter et al., 1988).
During the first 3 weeks of retrovirus infection, C57BL/6 mice present with a persistent
generalized lymphadenopathy that is associated with early polyclonal B cell activation, expan‐
sion, and hypergammaglobulinemia (Gazzinelli et al., 1992; Klinman and Morse, 1989; Morse et
al., 1995; Mosier et al., 1985). As MAIDS progresses, B cells become defective and are unable
to respond to antigen due to compromised immunoglobulin‐receptor signaling (Klinman and
Morse, 1989; Selvey et al., 1995). Sixteen‐weeks post retrovirus infection, B cell proliferation in
MAIDS mice slows and numbers of antibody‐secreting B cells decline, possibly due to bone mar‐
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row precursor exhaustion or to the alteration in CD4+ T cell cytokine production that occurs fol‐
lowing week 4 of infection (Klinman and Morse, 1989).
Alterations in the CD4+ T‐helper (Th) cell cytokine profile and profound dysfunction of cel‐
lular immunity in MAIDS mice become evident 3 to 4‐weeks after retrovirus infection. During
this time CD4+ T cells exhibit a shift in cytokine profile in the absence of antigen stimulation,
such that the levels of type‐1 (Th1) cytokines including IFN‐γ and IL‐2 become decreased and
levels of the type‐2 (Th2) cytokines IL‐4, IL‐6, and IL‐10 are increased (Gazzinelli et al., 1992). In
addition, concanavalin A stimulated CD4+ T cells isolated from MAIDS mice following this shift
in cytokine profile fail to produce IL‐2 or IFN‐γ (Gazzinelli et al., 1992). However, the impaired
ability of CD4+ T cells to respond to antigen or mitogen stimulation during MAIDS is not due to
a decline in CD4+ T cell numbers (Mosier et al., 1985), but rather the induction of anergy in
these CD4+ T cells (Muralidhar et al., 1992).
While innate immune responses from macrophages remain intact, this pivotal immu‐
nologic shift in CD4+ T cells leads to a progressive immunodeficiency characterized by abnormal
CD8+ T cell and natural killer cell responses (Morse et al., 1989; Umemura et al., 2001) at ap‐
proximately 8 weeks after retrovirus infection, which ultimately results in high susceptibility to
several opportunistic diseases including murine cytomegalovirus (MCMV) retinitis. In fact,
100% of mice with MAIDS of 10 weeks’ duration are susceptible to MCMV retinal disease by 10
days after subretinal MCMV inoculation (Dix and Cousins, 2004a). Moreover, the MAIDS‐related
MCMV retinal disease that develops presents with histopathologic features that closely resem‐
ble those observed in AIDS‐related HCMV retinitis, specifically development of a striking full‐
thickness retinal necrosis that replaces the normal architecture of the retinal tissues within days
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of virus infection in addition to hemorrhage, viral inclusions of the RPE, and cytomegalic cells
(Dix and Cousins, 2004a). Therefore, the MAIDS model of experimental MCMV retinitis presents
an attractive animal model to investigate the involvement of the CD4+ T cell cytokines IL‐17, IL‐
4, and IL‐10 in the context of AIDS‐related HCMV retinal disease development.

Table 1.1. Mouse model of retrovirus‐induced immunosuppression (MAIDS) development.

1 week

Polyclonal B cell activation

1‐3 weeks

Generalized chronic lymphadenopathy

3 weeks

Th1 to Th2 shift in cytokine profile

4 weeks

Depressed T cell functions

8‐10 weeks

Susceptible to opportunistic infections (MCMV
retinitis)

1.9

Immunology of HCMV Infection
Both the innate and adaptive immune responses are key factors for host protection

against HCMV‐related diseases, and thus understanding the immune response to HCMV infec‐
tion of the retina is of great importance for finding novel treatments of HCMV retinitis in
HIV/AIDS patients. Because HCMV has strict species specificity, studying the pathogenesis of
HCMV retinitis in HIV/AIDS patients has proved to be difficult. Thus MCMV, the mouse equiva‐
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lent of HCMV, has been utilized as it shares similar genomic structure and biological attributes
with HCMV including pathogenesis, immunomodulation, and latency (Hudson, 1979; Jordan,
1983).
Firstly, like the HCMV genome, the MCMV genome consists of 230 kbps with an overall
G+C content of 58% (Honess et al., 1989; Rawlinson et al., 1996). MCMV encodes for 170
genes, which are collinear with the central region of HCMV genome, spanning 180 kbps
(Rawlinson et al., 1996). In addition, approximately 78 MCMV genes share significant homology
with HCMV genes (Davison et al., 2003; Rawlinson et al., 1996). However, the ends of the
MCMV genome encode for MCMV‐specific glycoproteins (Rawlinson et al., 1996).
Secondly, MCMV can be transmitted between mice in a similar fashion that HCMV is
transmitted between humans. MCMV transmission typically occurs through direct contact with
saliva, as active MCMV replication is most prominent in the salivary glands of infected mice; in
addition, MCMV can also be transmitted through sexual contact (Hudson, 1979; Staczek, 1990).
Like HCMV, MCMV is able to infect numerous cells types in vivo including endothelial cells,
epithelial cells, dendritic cells, and macrophages, the site of MCMV latency (Hsu et al., 2009;
Jordan, 1983; Jordan and Takagi, 1983). MCMV infection of the immuocompetent mice is self‐
limited, but MCMV can become pathogenic in the immunocompromised mice to cause disease
including myocarditis, pneumonitis, and retinitis (Craighead et al., 1992; Mutter et al., 1988;
Shellam et al., 1985; Staczek, 1990). However, MCMV does not cross the placenta to cause cy‐
tomegalovirus‐related congenital disease as is seen with HCMV infection of a developing fetus
(Kashiwai et al., 1992; Tsutsui et al., 1993). Lastly, both HCMV and MCMV are susceptible to
treatment with the antiviral ganciclovir (Shanley et al., 1985). Due to all of the similarities be‐
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tween MCMV and HCMV, MCMV presents an ideal model for studying HCMV‐related disease
pathogenesis and has begun to improve our understanding of the host immune response dur‐
ing HCMV infection, specifically HCMV retinitis (Dix and Cousins, 2004a; Knipe and Howley,
2007).

1.9.1 Innate Immune Response to HCMV Infection
As reviewed by Paul, 2008, the host defense against pathogens is divided into two types
of responses: the innate immune response and the adaptive immune response. The innate
immune response is the first line of defense against microbes and is comprised of specific com‐
ponents that perform distinct functions to protect the host from infection. Numerous immune
cells including macrophages, neutrophils, and natural killer (NK) cells work to eliminate patho‐
gens through direct phagocytosis of microbes or through the directed killing of infected cells.
Virus‐infected cells are able to secrete type I interferons, interferon‐alpha (IFN‐α) and inter‐
feron‐beta (IFN‐β), which turn on interferon‐stimulated genes to induce an antiviral state in the
infected cell, resulting in decreased virus replication. Secretion of IFN‐α and IFN‐β from virus‐
infected cells also results in the activation of macrophages and NK cells.
Macrophages, mononuclear leukocytes, are highly abundant and widely distributed
throughout the lymphoidal and non‐lymphoidal organs of the body. Circulating monocytes give
rise to macrophages when they leave the peripheral blood and enter into the tissues (Gordon
and Taylor, 2005; Van Furth et al., 1973). Once in the tissues, activated, heterogenic macro‐
phages display numerous functions in order to maintain homeostasis in the host including the
phagocytosis of infected cells, the secretion of pro‐ or anti‐inflammatory cytokines, and the ac‐
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tivation of B and T cells (Gordon and Taylor, 2005). The activation of macrophages occurs via
the classical or alternative pathway (Mosser and Edwards, 2008). Classically activated macro‐
phages, also designated M1 macrophages, are induced through the secretion of IFN‐γ and TNF‐
α from CD4+ T‐helper type 1 cells and secrete pro‐inflammatory cytokines including IL‐6, IL‐23,
and IL‐1 in response to viral or bacterial infections (Cassetta et al., 2011; Gordon, 2007; Mosser
and Edwards, 2008; van Furth et al., 1972). Secretion of pro‐inflammatory IL‐6 and IL‐23 are
essential for the differentiation of the CD4+ Th17 lineage (Annunziato et al., 2010; Bettelli et al.,
2007). Macrophages (M2) alternatively activated through the secretion of IL‐4 and IL‐13 secre‐
tion from CD4+ T‐helper type 2 cells are anti‐inflammatory and promote wound healing
(Cassetta et al., 2011; Gordon, 2003; Mosser and Edwards, 2008; Sunderkotter et al., 1994).
During HCMV infection, macrophages are a double‐edged sword in that they help to
limit viral replication (Morahan et al., 1980), but are also the target of HCMV infection as well
as the site of viral latency (Rice et al., 1984; Tegtmeyer and Craighead, 1968). In addition, acti‐
vation of infected macrophages stimulates the replication of virus (Hanson et al., 1999), which
contributes to viral dissemination and potentially disease (Blasi, 2004; Vliegen et al., 2004).
M1 Macrophages are also a major source of tumor necrosis factor‐alpha (TNF‐α), an in‐
flammatory cytokine that initiates a broad range of cellular responses, ranging from the induc‐
tion of cellular apoptosis to the activation of inflammatory genes to the induction of the adap‐
tive immune response (Bacci et al., 2008; Vassalli, 1992). TNF‐α signaling occurs through two
receptors, TNF receptor 1 (TNFR1) and TNFR2 (Baud and Karin, 2001; Wajant et al., 2003).
TNFR1 signaling results in the activation of caspases, including caspase‐3 and ‐8, leading to cel‐
lular apoptosis (Bradley, 2008; Rahman and McFadden, 2006). On the other hand, TNFR2 sig‐
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naling results in cell survival and the production of inflammatory cytokines (Bradley, 2008;
Rahman and McFadden, 2006). TNF‐α is expressed in the eye of HIV/AIDS patients with HCMV
retinitis, and M1 macrophages are thought to be the source of TNF‐α in the ocular compart‐
ment of these individuals (Hofman and Hinton, 1992; Mondino et al., 1990). In addition, animal
studies by Dix and colleagues have linked increased TNF‐α production to experimental MCMV
retinitis in MAIDS mice (Dix and Cousins, 2004b), potentially from M1 macrophages.
NK cells are granular lymphocytes that are able to spontaneously lyse virus‐infected cells
and tumor cells in a perforin‐dependent manner (Altfeld et al., 2011; Paul, 2008). The lysing of
target cells by NK cells is induced by the lack of MHC class I on and/or the overexpression of NK
cell‐activating ligands on the target cells’ surfaces (Altfeld et al., 2011). NK cells produce antivi‐
ral cytokines such as IFN‐gamma (IFN‐γ) and TNF‐α as well as interact with T cells in order to
shape an effective adaptive immune response (Altfeld et al., 2011; Jackson et al., 2011).
Both the interferon response and NK cells a play crucial role in controlling early virus in‐
fection, including HCMV and MCMV infection. For example, mice treated with IFN‐α and IFN‐β
antibodies exhibited increased susceptibility to MCMV infection and thus increased MCMV viral
titers (Grundy and Melief, 1982; Grundy et al., 1982). Adoptive transfer of NK cells to neonate
mice that lack NK cells or to severe combined immunodeficiency (SCID) mice provided protec‐
tion against MCMV infection (Jackson et al., 2011; Tay et al., 1998). Mice with high levels of NK
cells exhibited a 10‐fold reduction in MCMV viral load (Knipe and Howley, 2007). When de‐
pleted of NK cells, mice were also susceptible to MCMV infection (Knipe and Howley, 2007). In
clinical studies, patients with NK cell defects experience recurrent HCMV‐related diseases
(Biron et al., 1989; Gazit et al., 2004; Quinnan et al., 1982).
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Other studies have established the protective role of NK cells in preventing MCMV reti‐
nal infection (Bigger et al., 1998; Inoue et al., 1993). Inoue and colleagues determined that
MCMV was detected in the eyes of BALB/c mice depleted of NK following systemic MCMV in‐
fection (Inoue et al., 1993). Additionally, when compared to healthy mice, NK cell‐depleted
mice exhibited increased ocular MCMV viral titers and exhibited retinal damage during in‐
travitreal MCMV infection (Inoue et al., 1993). The observations of Inoue and colleagues were
further verified by Bigger and coworkers who showed that BALB/c mice depleted of NK cells
were susceptible to MCMV retinitis (Bigger et al., 1998). In addition, Bigger and colleagues de‐
termined that poly(I‐C)‐activated NK cells were able to protect mice devoid of CD4+ T cells and
CD8+ T cells from MCMV‐related retinitis development (Bigger et al., 1998).
The importance of NK cells in the innate response to HCMV infection can also be in‐
ferred through the numerous HCMV viral proteins that inhibit the NK response. The HCMV
UL16, UL40, UL140, UL141, and UL142 proteins downregulate NK cell activity. For example,
UL16 directly downregulates the NK cell‐activation ligand NKG2D (Dunn et al., 2003a; Rolle et
al., 2003), UL40 binds to the host cell histocompatibility antigen E (HLA‐E) and inhibits its ex‐
pression (Tomasec et al., 2000), and UL141 downregulates the NK cell activation ligands CD155
and CD112 (Prod'homme et al., 2010; Tomasec et al., 2005). Similar to HCMV, MCMV viral pro‐
teins murine 138 (m138), m144, m145, and m155 also directly interact with and downregulate
NK cell activation ligands (Farrell et al., 1997; Lenac et al., 2006; Lodoen et al., 2004).
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1.9.2 Humoral Immune Response to HCMV Infection
As reviewed in Parham, 2005 and Paul, 2008, the adaptive immune response is com‐
prised of T cells and B cells that possess a more potent and specific response against pathogen
when compared to the innate immune response. Unlike the cells of the innate immune system,
adaptive immune system cells must first be exposed to foreign antigens, which delays the im‐
mune response such that antigen‐specific effector and memory cells can be differentiated.
However, upon a secondary exposure to the same antigen, memory cells immediately respond
via clonal expansion and effector actions in order to prevent disease development. The produc‐
tion of antigen‐specific antibodies by B cells is called the humoral response.
The humoral immune response is important for limiting viral replication and spread dur‐
ing early HCMV infection. Studies conducted in guinea pigs revealed that animals were pro‐
tected from disease development when either actively or passively immunized with guinea pig
CMV glycoprotein B (gB) (Schleiss et al., 2004b). Additionally, when pregnant guinea pigs were
vaccinated with guinea pig CMV gB or passive transfer of guinea pig immunoglobulin, fetal
transmission of CMV was prevented (Adler and Nigro, 2008; Jackson et al., 2011; Schleiss et al.,
2004b). A similar study conducted in pregnant women showed a reduction in fetal transmission
of HCMV when mothers received HCMV hyperimmune serum (Nigro et al., 2005). In addition,
maternal antibodies to HCMV were able to protect premature newborns against disease devel‐
opment (Fowler et al., 1992; Yeager et al., 1981), whereas mother‐to‐fetus transmission of
HCMV was increased in women with poorly neutralizing HCMV antibodies (Schleiss et al.,
2004a). Numerous HCMV proteins are immunogenic, including gB, gH, phosphoprotein 150
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(pp150), and pp52 (Knipe and Howley, 2007). Thus, in addition to limiting viral replication, an‐
tibodies against HCMV may play a role in limiting HCMV mother‐to‐fetus transmission.
While HCMV‐specific antibodies play are role in limiting viral replication, Dix and col‐
leagues determined that the passive transfer of MCMV hyperimmune serum or anti‐
glycoprotein B (gB) MCMV monoclonal antibodies to mice with retrovirus‐induced immunosup‐
pression prior to ocular MCMV infection failed to reduce the frequency and severity of MCMV
retinitis (Dix et al., 1997a). This work indicates that CMV‐specific antibodies are not sufficient
to prevent the development of HCMV retinitis, and that cell‐mediated immunity, rather than
humoral immunity, plays a critical role in protecting against CMV retinitis development.

1.9.3 Cell‐mediated Immune Response to HCMV Infection
The cell‐mediated immune response serves to protect the host against intracellular
pathogens including viruses through the actions of CD4+ T‐helper cells and cytotoxic CD8+ T
cells. As reviewed by Paul, 2008, the actions of cytotoxic CD8+ T cells are carried out via two
pathways: perforin‐mediated cell death pathway and Fas‐mediated cell death pathway. During
perforin‐mediated cytotoxicity, CD8+ T cells come into contact with infected target cells, and
their granule mediators, perforin and granzyme B, are polarized toward the target cell. Perforin
creates holes within the target cell membrane through which granzyme B is released (Liu et al.,
1995). Granzyme B cleaves pro‐caspase‐3 into its active form, resulting in DNA fragmentation,
leakage of mitochondrial proteins into the cytosol, and ultimately apoptosis of the infected tar‐
get cell (Andrade et al., 1998; Ewen et al., 2012; Van de Craen et al., 1997). The Fas‐mediated
cytotoxic pathway involves interactions of the Fas ligand on effector CD8+ T cells with the Fas
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protein expressed on target cells (Ju et al., 1995). This interaction signals the activation of
caspases, which results in apoptosis of the infected target cell. In addition, cell death can be
induced by the TNF‐related apoptosis‐inducing ligand (TRAIL) produced by CD8+ T cells
(Almasan and Ashkenazi, 2003; Wolkers et al., 2011). The binding of TRAIL to the death recep‐
tors 4 or 5 that are expressed on cells results in the activation of caspase‐8 and ‐10 and ulti‐
mately apoptosis (Almasan and Ashkenazi, 2003; Wolkers et al., 2011).
Cell‐mediated immunity is the most prominent host defense against HCMV infection
and thus HCMV‐related diseases. Studies have shown that CD8+ T cells control HCMV viral rep‐
lication and dissemination with assistance of NK cells and CD4+ T cells (Reddehase, 2000;
Reddehase et al., 1985; Riddell et al., 1992; Steffens et al., 1998). The importance of both CD4+
and CD8+ T cells in protection against HCMV‐related disease development can also be inferred
by number of viral proteins that inhibit the actions of these cells during infection. For example,
MCMV gp34, gp40, and gp48 are functional homologs of HCMV glycoproteins encoded by viral
genes US2, US3, and US11, respectively (Kavanagh et al., 2001). These viral glycoproteins de‐
crease MHC I protein expression on virus‐infected cells (Kattenhorn et al., 2004; Kavanagh et
al., 2001; Loewendorf and Benedict, 2010; Loewendorf et al., 2011; Mocarski, 2002; Wagner et
al., 2002), leading to decreased CD4+ T cell and CD8+ T cell activation. In addition, the MCMV‐
specific m155 protein inhibits expression of the CD4+ T cell and CD8+ T cell stimulator protein
CD40 in virus‐infected monocytes/macrophages as well as in virus‐infected dendritic cells
(Elgueta et al., 2009; Loewendorf et al., 2011; Ma and Clark, 2009). These viral proteins lead to
reduced CD4+ and CD8+ T cell activation during infection in order to delay virus recognition and
promote virus replication and dissemination. In addition, other studies have noted that the
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most severe HCMV‐related diseases occur in individuals with intact antibody responses but who
lack and/or have impaired T cell responses (Atherton et al., 1992; Boeckh et al., 2003; Cainelli
and Vento, 2002; Holbrook et al., 2000; Jabs, 2011; Knipe and Howley, 2007; Lang, 1972;
Rowshani et al., 2005; Rubin, 1989). The onset of HCMV retinitis occurs in HIV/AIDS patients
following the loss of cellular immunity, specifically a reduction in CD4+ T cell numbers (Atherton
et al., 1992; Dix and Cousins, 2004a; Holbrook et al., 2000; Jabs, 2011). These data suggest that
CD4+ and CD8+ T cells play a crucial protective role in HCMV retinitis disease pathogenesis.
Mouse studies have begun to determine the exact roles of CD4+ and CD8+ T cells in pro‐
tecting against HCMV‐related diseases including retinitis (Dix and Cousins, 2004a). Atherton
and colleagues noted that when BALB/c mice were treated with either anti‐CD4+ or anti‐CD8+
antibodies prior to subretinal MCMV injection, 80% of the CD8+ T cell depleted mice were sus‐
ceptible to MCMV retinitis while 30% of the CD4+ T cell depleted mice were retinitis susceptible
(Atherton et al., 1992). Additionally, adoptive transfer of MCMV‐specific CD8+ T cells to drug
immunosuppressed (methylprednisolone acetate) BALB/c mice prior to MCMV subretinal injec‐
tion resulted in protection against retinitis development (Bigger et al., 1999). More specifically,
Dix and colleagues determined that the CD8+ perforin‐mediated pathway, but not the Fas/FasL‐
mediated pathway, is essential for protection against experimental MCMV retinitis due to the
observation that only perforin knockout mice were susceptible to MCMV retinitis development
(Dix et al., 2003a).
Our laboratory is currently investigating the involvement of CD4+ T cell cytokines ex‐
pressed during HIV/AIDS, their influences over CD8+ T cell functions, and thus the potential
contributions of CD4+ T cell cytokines to HCMV‐related diseases specifically, retinitis. Dix and
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coworkers investigated the ability of the CD4+ T‐helper (Th) cell type 1 cytokine IL‐2 or the
CD4+ Th lineage activating cytokine IL‐12 to govern susceptibility to MCMV retinitis during ret‐
rovirus immunosuppression (Dix et al., 1997b). IL‐2 is a major immunoregulatory cytokine that
affects T cell, B cell and NK cell activity, and IL‐12 is an inducer of IFN‐γ and has been shown to
protective against parasitic infection as well as increase CD8+ T cell numbers during MCMV in‐
fection (Dix et al., 1997b). Administration of recombinant human IL‐2, but not recombinant
murine IL‐12, to mice with retrovirus‐induced immunosuppression prior to ocular MCMV infec‐
tion resulted in a significant decrease in ocular MCMV titers as well as a significant reduction in
the frequency and severity of MCMV retinitis (Dix et al., 1997b). Further studies of IL‐2 immu‐
notherapy during retrovirus‐induced immunosuppression revealed that the resistance to
MCMV retinitis was due to increased infiltration of perforin‐expressing CD8+ T cells into the
eyes of IL‐2 treated mice during ocular MCMV infection (Dix and Cousins, 2003b; Dix et al.,
2003b). We therefore wished to further investigate the potential of other CD4+ T cell cytokines
including IL‐4, IL‐10, and IL‐17 to govern susceptibility to experimental MCMV retinitis in mice
during retrovirus‐induced immunosuppression through the alteration of cellular immunity.

1.9.3.1 CD4+ T‐Helper Cell Cytokines
CD4+ T cells, more specifically, T‐helper (Th) cells, are involved in mediating the adaptive
immune response. Three subsets of Th cells are involved in protecting the body against foreign
invaders: Th1, Th2, and Th17 (Figure 1.4). The functions of these T cell subsets are correlated
with the types of cytokines they secrete. Th1 cells are involved in cell‐mediated immunity, pro‐
tecting the body against intracellular pathogens, and inducing delayed‐type hypersensitivity
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(DTH) through the release of their respective cytokines IFN‐γ and IL‐2 (Mosmann et al., 1986;
Mosmann and Sad, 1996). Th2 cells, on the other hand, mediate extracellular immunity and
the allergy response including the production of immunoglobulin E (IgE) through IL‐4, IL‐6, and
IL‐10 production (Mosmann et al., 1986; Mosmann and Sad, 1996). Th17 cells regulate acute
inflammation associated with autoimmune diseases and activate neutrophils through the secre‐
tion of IL‐17A, IL‐17F, TNF‐α, and IL‐6 (Bettelli et al., 2007; Furuzawa‐Carballeda et al., 2007;
Schmidt‐Weber et al., 2007). CD4+ Th2 cell cytokines are able to suppress Th1 cell function and
vice versa (Mosmann and Sad, 1996). Suppression of Th1 cell functions through increased pro‐
duction of Th2 cytokines leads to the suppression of cell‐mediated immunity (Mosmann and
Sad, 1996).

33

Figure 1.4. CD4+ T‐helper cell differentiation. When exposed to pathogens, antigen‐presenting
cells (APCs) like dendritic cells (DC) secrete cytokines. The type of cytokines secreted will in
turn cause the differentiation of particular CD4+ T‐helper cell subsets. For example, IL‐4 secre‐
tion leads to the development of Th2 helper subset from naïve T cells (Th0), which secretes IL‐4,
IL‐6, and IL‐10. An IL‐12‐dominated environment leads to Th1 lineage development, which se‐
cretes IL‐2 and IFN‐γ. Secretion of IL‐6 from APCs and TGF‐β from T regulatory cells (Treg) leads
to the development of the Th17 subset, which is further stabilized by IL‐23 secretion from APCs.
The Th17 subset secretes IL‐17. Based on (Afzali et al., 2007).
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1.9.3.2 Interleukin‐4 (IL‐4)
The Th2 cytokine IL‐4 is an immunomodulatory cytokine that has a broad range of cellu‐
lar targets (Paul, 2008). Located on chromosome 5 within a group of cytokine genes, four exons
encode the 129‐amino acid secreted protein, which consists of four α‐helices connected with
short β‐sheets (Chomarat and Banchereau, 1997, 1998; Paul, 2008). IL‐4 is able to promote the
CD4+ Th2 phenotype, alternatively activate macrophages, decrease the secretion of inflamma‐
tory cytokines, act as a B cell growth factor, promote immunoglobulin class switching (IgE), and
induce MHC class II and CD23 expression (Paul, 2008). These biological functions are accom‐
plished through the binding of IL‐4 to its two‐chain receptor, which is expressed at varying lev‐
els on both immune and non‐immune cells (Brown and Hural, 1997).
Loss of cell‐mediated immunity, during HIV infection for example, leads to increased
production of Th2 cytokines such as IL‐4 (Clerici and Shearer, 1993). Dix and colleagues noted a
significant increase in IL‐4 mRNA levels within eyes of mice with MAIDS that develop MCMV
retinitis (Dix and Cousins, 2003a). Increased IL‐4 production leads to increased Fas‐ligand (FasL)
expression and decreased perforin expression on T cells (Aung and Graham, 2000). Addition‐
ally, perforin knockout mice were susceptible to MCMV retinitis development (Dix and Cousins,
2003a; Dix et al., 2003a). Keinzle et al. determined that increased IL‐4 production was associ‐
ated with a decrease in granzyme B expression in CD8+ cytotoxic T cells (Kienzle et al., 2002;
Kienzle et al., 2005). Based on these findings, we wished to investigate whether increased pro‐
duction of IL‐4 during HIV infection governs susceptibility to AIDS‐related HCMV retinitis
through the direct downregulation of perforin and granzyme B from CD8+ cytotoxic T cells util‐
izing our MAIDS model of experimental cytomegalovirus retinitis.
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1.9.3.3 Interleukin‐10 (IL‐10)
IL‐10 is an anti‐inflammatory cytokine secreted by numerous immune cells including
macrophages, dendritic cells, CD4+ T cells, and CD8+ T cells (Couper et al., 2008; Paul, 2008).
Located on chromosome 1, IL‐10 consists of 160 amino acids, which fold into a non‐covalently
bonded homodimer (Moore et al., 2001; Ouyang et al., 2011; Paul, 2008). Actions of IL‐10 are
carried out via binding its two‐chain IL‐10 receptor, leading to the activation of the Janus kinase
(Jak)/signal transducer and activator of transcription (STAT) pathway and ultimately to the acti‐
vation of STAT‐3, STAT‐1, and STAT‐5 (non‐macrophage cells) (Moore et al., 2001; Ouyang et al.,
2011). IL‐10 acts to inhibit the production of IFN‐γ as well as other cytokines secreted from Th1
cells (Ouyang et al., 2011; Paul, 2008).
IL‐10 is able to regulate IL‐17 secretion from CD4+ Th17 cells by binding its receptor ex‐
pressed on Th17 cells (Chaudhry et al., 2011; Huber et al., 2011). The HIV Tat protein induces
IL‐10 production by monocytes (Ji et al., 2005; Leghmari et al., 2008). MCMV infection also in‐
duces expression of IL‐10 in CD4+ T cells as well as in virus‐infected macrophages (Akhtar et al.,
2010; Humphreys et al., 2007; Redpath et al., 1999). Increased production of IL‐10 during
MCMV infection leads to reduction of MHC class II on infected cells and thus a decreased host
response (Redpath et al., 1999).
In addition to controlling IL‐17 secretion from Th17 cells, IL‐10 production is able to alter
CD8+ T cell mediated cytotoxicity, subsequently delaying pathogen clearance. For example, dur‐
ing HIV infection, IL‐10‐producing CD8+ T cells specific for HIV were associated with a decreased
cytolytic response to HIV, as well as to other viruses including HCMV (Elrefaei et al., 2007). De‐
pletion of these HIV‐specific IL‐10‐producing CD8+ T cells, however, resulted in increased IL‐2
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production and increased cytolysis of virus‐infected cells (Elrefaei et al., 2007). In addition,
overexpression of IL‐10, alone or in conjunction with IL‐4, promoted the expression of FasL on
CD4+ T cells (Dace et al., 2009; Furukawa et al., 2008). Due to the fact that previous studies
suggest an association between increased IL‐10 production and suppressed cellular immunity,
especially cellular immunity involving perforin‐mediated cytotoxicity, we investigated whether
increased IL‐10 during HIV/AIDS governs susceptibility to AIDS‐related HCMV retinitis.

1.9.3.4

Interleukin‐17 (IL‐17)
A recently recognized CD4+ T‐helper subset (Th17) uniquely secretes IL‐17 (also known

as IL‐17A), in addition to IL‐17F, TNF‐α, and IL‐6 (Furuzawa‐Carballeda et al., 2007). The differ‐
entiation of the Th17 linage is dependent upon the secretion of IL‐6 and TGF‐β from APCs
(Bettelli et al., 2007). The Th17 linage is then stabilized through the secretion of IL‐23 from
APCs (Bettelli et al., 2007). Located on chromosome 6, IL‐17 consists of 155 amino acids that
form a homodimer or a heterodimer with IL‐17F. While IL‐17F only shares 50% homology with
IL‐17A (IL‐17) on the protein levels, it is a functional homolog of IL‐17 (Weaver et al., 2007). Ac‐
tions of IL‐17 are carried out though binding to its receptor, IL‐17RA (Weaver et al., 2007). IL‐17
is a pro‐inflammatory cytokine that is involved with recruitment of macrophages and neutro‐
phils, as well as enhancement of the protective activities carried out by CD4+ T cells during the
adaptive immune response (Stockinger et al., 2007). This pro‐inflammatory cytokine, however,
has been associated with cellular damage seen in various autoimmune diseases like rheumatoid
arthritis and multiple sclerosis (Furuzawa‐Carballeda et al., 2007). Additionally, recent work
conducted by Luger and colleagues has linked increased IL‐17 secretion to uveitis, an autoim‐
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mune disease of the eye that causes vision loss and blindness in up to 10% of the population in
the Untied States (Luger et al., 2008). Though Th17 cells have been implicated to be involved in
various autoimmune diseases, the role of IL‐17 secretion HIV infection remains controversial,
and its role in AIDS‐related HCMV retinitis is unknown (Brenchley et al., 2008; Maek et al.,
2007; Yue et al., 2008). It is possible that this pro‐inflammatory cytokine is increased during HIV
infection and that increased IL‐17 production directly contributes to the pathogenesis of AIDS‐
related HCMV retinitis. We therefore focused our studies on the whether IL‐17 governs suscep‐
tibility to experimental MCMV retinitis in MAIDS mice.

1.9.4 Suppressor of Cytokine Signaling 1 (SOCS‐1) and SOCS‐3
The nature and the length of the immune response to pathogens is determined by the
responses initiated and received by effector T cells (Yoshimura et al., 2007). Therefore, nega‐
tive‐feedback loops are essential for controlling the immune response such that dysregulation
and ultimately tissue damage does not occur. One negative‐feedback system that is induced
through immune cell cytokine secretion involves the intracellular proteins suppressor of cyto‐
kine signaling‐1 (SOCS‐1) and SOCS‐3 (Yoshimura et al., 2007). Eight different SOCS proteins
have been identified, but SOCS‐1 and ‐3 proteins are unique proteins that contain a kinase in‐
hibitory region (KIR) (Akhtar and Benveniste, 2011; Sabat et al., 2010; Yoshimura et al., 2007).
The KIR acts to directly inhibit the activation of cytokine signaling through the Jak/STAT proteins
associated with various cytokine receptors (Akhtar and Benveniste, 2011; Yoshimura et al.,
2007).
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1.9.4.1 SOCS‐1 and SOCS‐3 in T cell Development, Differentiation, and Regulation
SOCS‐1 regulates the development of T cells in the thymus, specifically the positive and
negative selection of T cells (Yoshimura et al., 2007). In addition, SOCS‐1 is important in regu‐
lating the activation and proliferation of CD8+ T cells via cytokines IL‐7 and IL‐15 (Yoshimura et
al., 2007). SOCS‐1 acts to suppress Th1 and Th2 differentiation depending on the cytokine envi‐
ronment (IL‐12 versus IL‐4) and negatively regulates IFN‐γ production (Yoshimura et al., 2007).
Due to the fact that SOCS‐1 can inhibit both Th1 and Th2 signaling, upregulation of SOCS‐1 is
thought to be a suppressor of both Th phenotypes (Yoshimura et al., 2007).
SOCS‐3 inhibits IL‐12 activation through directly binding to STAT4; overexpression of
SOCS‐3 leads to a predominately Th2 phenotype (Yoshimura et al., 2007). Additionally, high
SOCS‐3 levels correlate with high levels of IgE expression (Yoshimura et al., 2007). SOCS‐3 is
also able to negatively regulate Th17 cell differentiation through the suppression of STAT3 acti‐
vation of IL‐6 and IL‐23 by directly binding to STAT3 on their receptors in Th17 cells (Yoshimura
et al., 2007).
Viruses, including influenza, respiratory syncytial virus (RSV), HIV, and HSV‐1 are able to
exploit SOCS proteins in order to evade the immune system. For example, HSV‐1, RSV, and HIV
induction of SOCS‐3 results in the inhibition of the antiviral interferon response and thus leads
to increased viral replication increased during HIV infection (Akhtar et al., 2010; Yoshimura et
al., 2007). Additionally, induction of SOCS‐1 by HSV‐1 inhibits STAT1 activation by IFN‐γ result‐
ing in increased viral replication (Frey et al., 2009). MCMV may or may not act in a similar
manner to activate SOCS‐1 and SOCS‐3 proteins. We therefore wished to investigate whether
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SOCS‐1 and ‐3 govern the secretion of Th2 and Th17 cytokines and thus indirectly contribute to
MCMV‐related retinitis pathogenesis.

1.10 Goals of This Dissertation
1.10.1 Specific Aim 1: Test the Hypothesis that the increase in CD4+ T Cell Cytokines IL‐4 or IL‐
10 downregulates cellular immunity to Increase Susceptibility to Experimental MCMV
Retinitis in Mice with MAIDS.
HCMV infection of the retina of untreated HIV/AIDS patients can cause the development of
a severe sight‐threatening retinal necrosis. The classic paradigm shift of CD4+ T cell cytokines
from a Th1‐dominant phenotype to a Th2‐dominant phenotype during HIV infection results in
the increase of Th2 cytokines including IL‐4 and IL‐10 (Clerici and Shearer, 1993; Ji et al., 2005;
Leghmari et al., 2008). Studies conducted by Dix and colleagues noted a significant increase in
IL‐4 mRNA levels within the eyes of MAIDS mice that develop MCMV retinitis (Dix and Cousins,
2003a). Increased IL‐4 production as well as increased IL‐10 production leads to an increased
Fas‐ligand (FasL) expression and decreased perforin expression on T cells (Aung and Graham,
2000; Oshima et al., 2007; Saito et al., 1999). Additionally, perforin knockout mice are suscep‐
tible to MCMV retinitis (Dix and Cousins, 2003a; Dix et al., 2003a). Keinzle and coworkers also
determined that IL‐4 production was also associated with a decrease in granzyme B expression
from CD8+ cytotoxic T cells (Kienzle et al., 2002; Kienzle et al., 2005). If IL‐4 and/or IL‐10 are
involved in increased susceptibility to MCMV retinitis, then neutralization of IL‐4 or IL‐10 during
MAIDS should result in resistance to MCMV retinitis. We therefore proposed a series of ex‐
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periments in order to determine whether loss of IL‐4 or IL‐10 during MAIDS results in resistance
to MCMV retinitis, possibly through the restoration of granzyme B and perforin.

1.10.2 Specific Aim 2: Test the Hypothesis that increased production of IL‐17 from CD4+ Th17
Cells Contributes to the Pathogenesis of Experimental MCMV Retinitis in Mice with
MAIDS.
IL‐17 has been associated with cellular damage seen in various autoimmune diseases
like rheumatoid arthritis and multiple sclerosis (Furuzawa‐Carballeda et al., 2007). The role of
IL‐17 secretion in HIV infection, however, remains unclear. Therefore, a series of experiments
were performed to determine IL‐17 levels in both whole splenic cells and enriched CD4+ T cells
during MAIDS progression. Additionally, recent work conducted by Luger and colleagues has
tied increased IL‐17 expression to the ocular autoimmune disease uveitis (Luger et al., 2008).
To further elucidate the role of IL‐17 in MCMV‐infected eyes of MAIDS mice, we performed a
series of experiments correlating intraocular IL‐17 expression with MCMV retinitis susceptibil‐
ity.
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2
2.1

METHODS AND MATERIALS
Animals
Wild‐type female C57BL/6 mice, IL‐4 ‐/‐ female mice on a C57BL/6 background, and IL‐

10 ‐/‐ female mice on a C57BL/6 background were purchased from Jackson Laboratories (Bar
Harbor, ME). Mice were housed in pathogen‐free conditions, allowed unlimited access to food
and water, and maintained in alternating 12‐hr light/dark cycles. All animal procedures were
conducted in accordance with Georgia State University Institutional Animal Care and Use Com‐
mittee (IACUC) policies as well as the ARVO Statement for Use of Animals in Ophthalmic and
Vision Research.

2.2

Viruses
Stocks of MCMV (Smith strain, American Type Culture Collection, Manassas, VA) and the

murine retrovirus mixture (LP‐BM5) (kindly provided by the AIDS Research and Reference Rea‐
gent Program, Germantown, MD) were prepared and stored as previously described (Dix et al.,
1994).

2.3

Induction of MAIDS
MAIDS was induced in 3‐week‐old wild‐type mice, IL‐4 ‐/‐ mice, and IL‐10 ‐/‐ mice with

the LP‐BM5 retrovirus mixture by i.p. injection as described previously (Dix et al., 1994). Mice
with MAIDS of 4‐weeks duration (MAIDS‐4), 8‐weeks duration (MAIDS‐8), and 10‐weeks dura‐
tion (MAIDS‐10) were used throughout the investigation.
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2.4
2.4.1

MCMV infection of mice
Systemic MCMV infection
Mice with MAIDS and healthy age‐matched mice were systemically infected with a sub‐

lethal dose of MCMV [1 X104 plaque forming units (PFU)] by i.p. inoculation.

2.4.2 Subretinal MCMV infection.
Eyes of wild‐type MAIDS‐8 mice, IL‐4 ‐/‐ MAIDS‐8 mice, and IL‐10 ‐/‐ MAIDS‐8 mice were
inoculated with MCMV as described previously (Dix et al., 1994). Briefly, 2 ul of maintenance
medium containing 1 X 104 plaque‐forming units (PFU) of MCMV was injected subretinally into
the left eye of each mouse. The right eye of each mouse was injected subretinally with 2 ul of
maintenance medium only and served as control for all investigations.

2.5

Splenic CD4+ T cell, macrophage, and Gr‐1+ cell isolation and enrichment
Whole spleens were collected from euthanized MAIDS mice with or without systemic

MCMV infection as well as from euthanized healthy, age‐matched mice with or without sys‐
temic MCMV infection. Immediately after removal, whole spleens were placed in Dulbecco’s
minimal essential medium (DMEM) (Cellgro, Manassas, VA), teased apart, and pushed through
a 210‐µm nylon mesh screen. The resulting splenic cell suspension was treated with Gey’s solu‐
tion (Sigma Aldrich, St. Louis, MO) for lysis of red blood cells, and processed for enrichment of
individual splenic cell populations according to the protocol provided by Miltenyi Biotec (Cam‐
bridge, MA). Enrichment of splenic CD4+ T cells was accomplished by the addition of CD4+ mi‐
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crobeads (Miltenyi Biotec) followed by the addition of anti‐CD4+ FITC‐labeled antibody
(Miltenyi Biotec) to the splenic cell suspension. Enrichment of splenic macrophages was ac‐
complished by the addition of anti‐F4/80‐PE antibody for 10 min in the dark at 4°C (eBio‐
science, San Diego, CA) followed by the addition of anti‐PE microbeads (Miltenyi Biotec) to the
splenic cell suspension. Enrichment of GR‐1+ cells (including neutrophils) was accomplished by
the addition of anti‐Gr‐1‐PE antibody (Miltenyi Biotec) for 10 min in the dark at 4°C followed by
the addition of anti‐PE microbeads (Miltenyi Biotec) to the splenic cell suspension. Following
incubation of all cell suspensions for 10 min in the dark at 4°C and an additional wash with 1 ml
of MACS buffer [phosphate buffered saline (PBS) (Cellgro, Manassas, VA), 2 mM ethylenedia‐
minetetraacetic acid (EDTA) (Sigma Aldrich, St. Louis, MO), and 0.5% bovine serum albumin
(BSA) (Fisher Scientific, Pittsburgh, PA)], all cell suspensions were applied to magnetic columns
as described in the manufacturer’s instructions (Miltenyi Biotec), and the resulting eluents con‐
taining the labeled CD4+ T cell and Gr‐1+ cell populations were sorted via flow cytometry (BD
FACS Aria III, BD Biosciences, San Jose, CA) to achieve an enrichment purity of > 90%.

2.6

Total RNA extraction
Total RNA was extracted from whole splenic cells, enriched populations of splenic cells,

and whole eyes using Trizol (Invitrogen, Grand Island, NY) coupled with the PureLink RNA mini
kit (Invitrogen) as per manufacturer’s instructions. Extracted total RNA was stored at ‐80 °C.
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2.7

Quantitative real‐time RT‐PCR assay
Total RNA was extracted from whole splenic cells and from whole eyes using Trizol (Invi‐

trogen, Grand Island, NY) coupled with the PureLink Micro‐to‐Midi Total RNA Purification Sys‐
tem (Invitrogen) per manufacturer’s instructions. Extracted total RNA was stored at ‐80C prior
to processing. Extracted total RNA was subjected to reverse transcription following the Super‐
Script III First‐Strand System for RT‐PCR (Invitrogen) protocol. cDNA was stored at ‐20C prior to
processing. cDNA from whole splenic cells and whole eyes from all animals was subjected to
quantitative real‐time RT‐PCR to determine the amount of transcripts specific. Murine GAPDH
cDNA (Qiagen) served as endogenous control. Briefly, 1.2 ul of cDNA was added to a reaction
mixture of 15 ul of Power SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA), 3 ul of
primers for each gene (see Table 2.1), 9.9 ul of double‐distilled water, and 0.9 ul of dimethylsul‐
foxide (Sigma, St. Louis, MO) for a total volume of 30 ul per reaction. Parameters for each quan‐
titative RT‐PCR assay cycle were 15 min at 95C, 15 sec at 94C, 31 sec at 55C, and 35 sec at 72C
for a total of 45 cycles. Transcription levels were determined utilizing the 7500 Fast Real‐Time
PCR System (Applied Biosystems), and average threshold cycles (Ct) were determined using the
7500 Fast Real‐Time PCR System software (Applied Biosystems).
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Table 2.1. Sequences, annealing temperature, and expected fragment size of primers used in
real‐time RT‐PCR assay.
Gene
Source
Primer
Annealing
AMP Length (bp)
(Accession
Sequence
Temperature
(°C)
Number)
IL‐4
Qiagen
QuantiTect
55
104
(NM_021283)
Primer Assay
IL‐10
Qiagen
QuantiTect
55
103
(NM_010548)
Primer Assay
Perforin
Qiagen
QuantiTect
55
123
(NM_011073)
Primer Assay
Granzyme B
Qiagen
QuantiTect
55
149
(NM_013542)
Primer Assay
Fas Ligand
Qiagen
QuantiTect
55
99
(NM_010177)
Primer Assay
Mm_IL-17A

Integrated DNA

Sense- CCT

(NM_010552)

Technologies

GGC GGC TAC

55

63

55

50

55

128

55

144

AGT GAA G
Antisense- TTT
GGA CAC GCT
GAG CTT TG
Mm_IL-23 (p19)

Integrated DNA

Sense- GGT

(NM_031252)

Technologies

TGA GCG GAA
T
Antisense- AGG
GAG TGG GAA
C

Mm_IL-6

Qiagen

(NM_031168)
Mm_GAPDH
(NM_008084)

QuantiTect
primer assay

Qiagen

QuantiTect
primer assay
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2.8

ELISA
Whole splenic cells and whole eyes from all animals were collected, individually stored

in liquid nitrogen, thawed, individually homogenized in 1.0 ml of phosphate‐buffered saline
(PBS) containing a protease inhibitor cocktail (Sigma), and individually stored at ‐20C prior to
performance of ELISA. At time of ELISA, homogenates were thawed, sonicated, clarified by cen‐
trifugation, and the resulting supernatants were subjected to ELISA for quantification of murine
IL‐4, IL‐10, or IL17 protein using the commercially available kit provided by eBioscience (San Di‐
ego, CA) per manufacturer’s instructions. Total protein for each sample was determined using
the Bradford Protein Assay (BioRad, Hercules, CA).

2.9

Western blot analysis
Whole spleens and whole eyes were collected from uninfected MAIDS ‐4, MAIDS‐8, and

MAIDS‐10 animals, individually stored in liquid nitrogen, thawed, and individually homogenized
in 1 ml of PBS containing protease inhibitor cocktail (Sigma). Standard Western blot analysis
was performed for detection of IL‐17 and GAPDH proteins using rabbit‐anti‐human IL‐17 anti‐
body (1:200) (Santa Cruz Biotechnology) or rabbit‐anti‐mouse GAPDH antibody (1:3000) (Sigma)
as primary antibodies, respectively. Following incubation with ImmunoPure goat anti‐rabbit IgG
antibody (heavy plus light chains [H+L]) (1:5000) (Thermo Scientific) secondary antibody, the
resulting nitrocellulose membrane (BioRad) was treated with chemiluminescence (ECL) West‐
ern blot detection reagents (GE Healthcare, Piscataway, NJ) and exposed to BioMax light film
(Kodak, Rochester, NY).
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2.10 Histopathology
Whole eyes collected from all animals were immediately fixed in 10% buffered formalin
(Electron Microscopy Sciences, Hartford, PA) for at least 48 hr at 4C, frozen in Optimal Cutting
Temperature (OCT) medium (Thermo Scientific, Rochester, NY), cut into 8‐um sections using a
Shandon Special Motorized Electronic Cryotome (Thermo Scientific), and sections were col‐
lected onto positively charged microscope slides (Thermo Scientific). Hematoxylin and eosin
staining was performed as previously described (Dix et al., 1994) with minor modifications. Ocu‐
lar sections were scored for frequency and severity of retinitis using a scoring system estab‐
lished by us previously (Dix et al., 1994).

2.11 Immunohistochemical staining of ocular tissues
Formalin‐fixed eyes were then frozen in O.C.T. medium (Thermo Scientific, Rochester,
NY) and cut using a Shandon Special Motorized Electronic Cryotome (Thermo Scientific) into 8‐
µm sections that were placed onto positively charged microscope slides (Thermo Scientific).
Immunohistochemical staining was performed by incubating slides with eye sections in 10 mM
sodium citrate (Sigma Aldrich) for 10 min at room temperature followed by a 5‐min rinse with
PBS (Cellgro) at room temperature. Immunohistochemical staining for IL‐17 in retinal tissues
was accomplished by reacting slides with rehydrated eye sections with polyclonal rabbit anti‐
hIL‐17 IgG (1:50) (Santa Cruz Biotechnology, Santa Cruz, CA) or with polyclonal normal rabbit
IgG (1:400) (control, Santa Cruz Biotechnology), processed using the rabbit ABC Staining System
(Santa Cruz Biotechnology), and stained with Vector Red alkaline phosphatase substrate (Vec‐
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tastain ABC‐AP Kit, Vector Laboratories, Burlingame, CA). Slides were counterstained with DAPI
(Vector Laboratories).
Double immunohistochemical staining for the identification of IL‐17 producing retinal
cells was accomplished by incubating rehydrated eye sections with rabbit‐anti‐hIL‐17 IgG (1:50)
(Santa Cruz Biotechnology) and goat anti‐hRhodopsin IgG (1:200) for identification of rod cells
(Santa Cruz Biotechnology) or goat anti‐hOpsinSW IgG for identification of cone cells (1:200)
(Santa Cruz Biotechnology) at 4 °C overnight in a humidified atmosphere. Following three
washes for 5 min with PBS, retinal sections were reacted with secondary antibodies, donkey
anti‐goat DyLight488 (1:300) (Jackson ImmunoResearch Laboratories INC, West Grove, PA) and
chicken anti‐rabbit DyLight594 (Jackson ImmunoResearch Laboratories INC) and incubated in
the dark at room temperature for 1 hr in a humidified atmosphere. Sections were washed three
times with PBS, mounted with medium containing DAPI (Vector Laboratories). All stained sec‐
tions were viewed at 200x or 400x magnification.

2.12 Recovery and quantification of infectious MCMV
Whole MCMV‐infected eyes were collected from wild‐type MAIDS‐8 mice, IL‐4 ‐/‐
MAIDS‐8 mice, and IL‐10 ‐/‐ MAIDS mice at 10 days after subretinal injection and individually
stored in liquid nitrogen prior to processing. At time of quantitative plaque assay, individual
eyes were thawed, individually homogenized on ice in 1.0 ml of cold Delbecco’s Minimal Essen‐
tial Medium (DMEM) (Cellgro, Manassas, VA), and clarified by centrifugation. Ten‐fold dilutions
of the resulting supernatants were titered onto monolayers of mouse embryo fibroblast (MEF)
cells in 6‐well plates, allowed to adsorb for 1‐hr at 37C in a humidified atmosphere of 5% CO2,
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overlaid with 1.0 ml DMEM, and incubated for 5 days at 37C in a humidified atmosphere of 5%
CO2. Individual plaques were counted using an inverted light microscope, and results were ex‐
pressed as the number of PFU per ml per whole eye (PFU/ml/eye).

2.13 Statistical analysis
All quantitative data obtained from quantitative real‐time RT‐PCR assay and ELISA were
expressed as means + standard error of mean (SEM) or standard deviation (SD), respectively. At
least two independent experiments per performed for each study. Statistical analysis was per‐
formed using the Wilcoxon‐rank sum or Student T‐test. A p value of < 0.05 was considered sig‐
nificant.
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3

AIM 1: TEST THE HYPOTHESIS THAT THE INCREASE IN CD4+ T CELL CYTOKINES IL‐4 OR IL‐
10 DOWNREGULATE CELLULAR IMMUNITY TO INCREASE SUSCEPTIBILITY TO
EXPERIMENTAL MCMV RETINITIS IN MICE WITH MAIDS
The data in this aim were published in Ophthalmology and Eye Diseases, 2012.

3.1

Introduction
IL‐4 and IL‐10 are key Th2 cytokines whose production is stimulated systemically during

AIDS (and therefore during AIDS‐related HCMV retinitis) as a result of HIV‐induced Th2 domi‐
nance. IL‐4 is an immunomodulatory Th2 cytokine that promotes a number of diverse immu‐
nological functions through binding to its two‐chain receptor (IL4R) that is expressed on both
immune and non‐immune cells (Brown and Hural, 1997; Keegan and Zamorano, 1998). Al‐
though the immunological outcome(s) of IL‐4 secretion varies remarkably depending on effec‐
tor cell, target cell, and the microenvironment in which IL‐4 is secreted (Brown and Hural, 1997;
Chomarat and Banchereau, 1997, 1998), IL‐4 promotes a number of diverse immunological
functions that impact macrophage differentiation, the differentiation of CD4+ T cells into Th2
cells, and the inhibition of secretion of various inflammatory cytokines (Paul, 2008). In compari‐
son, IL‐10 is an anti‐inflammatory Th2 cytokine that inhibits the production of INF‐g as well as
other Th1 cytokines (Ouyang et al., 2011; Paul, 2008), an accomplishment achieved through
binding of IL‐10 to its two‐chain receptor composed of an alpha and beta subunit (Moore et al.,
2001; Ouyang et al., 2011).
Of greater significance, however, are observations that CD8+ T‐cell‐mediated cytotoxicity
is remarkably diminished at times of increased IL‐4 and/or IL‐10 production. For example, in‐
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creased IL‐4 production during HIV infection results in conversion of cytotoxic CD8+ T cells to
CD8‐ T cells that also produce more IL‐4, further suppressing the Th1 response (Brown and
Hural, 1997; Erard et al., 1994; Erard et al., 1993). HIV infection also results in IL‐10‐producing
CD8+ T cells that exhibit reduced cytolytic activity to HIV as well as other viruses including
HCMV (Elrefaei et al., 2007). Overexpression of IL‐4 in mice also results in increased Fas‐ligand
(FasL) expression on T cells and a concomitant decrease in perforin production, an important
observation that suggests that IL‐4 favors Fas/FasL‐mediated cytotoxicity over perforin‐
mediated cytotoxicity (Aung and Graham, 2000). Similar results have also been observed during
overexpression of IL‐10 (Dace et al., 2009; Furukawa et al., 2008). Taken together, these find‐
ings suggest a pivotal association between increased IL‐4 and/or IL‐10 production during retro‐
virus‐induced immunosuppression and suppressed cellular immunity, especially cellular immu‐
nity involving perforin‐mediated cytotoxicity.
Using our MAIDS model of MCMV retinitis, we demonstrated previously that loss of the
perforin cytotoxic pathway is responsible for increased susceptibility to MCMV retinitis during
MAIDS (Dix et al., 2003a), and this increased susceptibility can be reversed by immunotherapy
with the Th1 cytokine IL‐2 (Dix et al., 1997b). Moreover, MCMV‐infected eyes of MAIDS animals
susceptible to MCMV retinitis contain high amounts of IL‐4 (Dix and Cousins, 2003a). These ob‐
servations, coupled with those from other laboratories showing that either IL‐4 or IL‐10 favor
the Fas/FasL cytotoxic pathway over the perforin cytotoxic pathway (Aung and Graham, 2000;
Baschuk et al., 2007; Dace et al., 2009; Furukawa et al., 2008; Kienzle et al., 2002; Kienzle et al.,
2005; Oshima et al., 2007; Saito et al., 1999), lead to the attractive hypothesis that an increase
in systemic production of IL‐4 or IL‐10 during retrovirus‐induced immunosuppression is respon‐

52

sible for increased susceptibility to MCMV retinitis during MAIDS. To our surprise, however, this
hypothesis proved to be incorrect since mice with MAIDS deficient in either IL‐4 or IL‐10 exhib‐
ited a frequency of retinitis, a severity of retinitis, and intraocular amounts of infectious virus
equivalent to those found in wild‐type mice with MAIDS.
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3.2

Results

3.2.1 Quantification of splenic IL‐4 and IL‐10 mRNA levels in wildtype C57BL/6 mice during
progression of MAIDS
Early work by Gazzinelli and colleagues (Gazzinelli et al., 1992; Morse et al., 1995) dem‐
onstrated that progression of MAIDS is associated with a shift in cytokine production by splenic
CD4+ T cells from a Th1 profile to a Th2 profile as seen in HIV‐infected patients with AIDS
(Clerici and Shearer, 1993), and this shift commences at ~3 weeks after retrovirus infection (Dix
and Cousins, 2004a). Although we have shown previously that IL‐4 mRNA levels increase signifi‐
cantly within the ocular compartment of MCMV‐infected eyes of mice with MAIDS (Dix and
Cousins, 2003a), we sought to confirm that our animals in the absence of MCMV infection also
exhibit a systemic increase in Th2 cytokines during the progression of MAIDS, especially for the
Th2 cytokines IL‐4 and IL‐10 that have been associated with dampening of cellular immunity
(Aung and Graham, 2000; Baschuk et al., 2007; Dix et al., 2003a; Kienzle et al., 2002; Kienzle et
al., 2005). Initial experiments using quantitative RT‐PCR assay were therefore performed to
measure IL‐4 and IL‐10 mRNA levels within splenic cells collected from wild‐type C57BL/6 mice
with MAIDS of 4‐weeks duration (MAIDS‐4), 8‐weeks duration (MAIDS‐8), and 10‐weeks dura‐
tion (MAIDS‐10), but without ocular MCMV infection. Results are shown in Fig. 3.1. Whereas
splenic IL‐4 mRNA levels increased nearly 2‐fold in MAIDS‐4 and MAIDS‐8 animals, MAIDS‐10
animals showed a significant 4‐fold increase in splenic IL‐4 mRNA levels (Fig 3.1A). In compari‐
son, splenic IL‐10 mRNA levels also increased during progression of MAIDS, but this increase
was evident later in the course of MAIDS and far greater than that seen for splenic IL‐4 mRNA.
Whereas no significant increase in IL‐10 mRNA was observed in splenic cells collected from
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MAIDS‐4 animals, splenic IL‐10 mRNA levels were ~4‐fold and ~17‐fold higher in MAIDS‐8 and
MAIDS‐10 animals, respectively (Fig 3.1B). Thus, as expected (Dix and Cousins, 2003a; Dix et al.,
1994; Morse et al., 1995) , our mice with MAIDS did indeed exhibit increased systemic produc‐
tion of IL‐4 and IL‐10 mRNAs during progression of retrovirus‐induced immunosuppression as
measured using splenic cells, although the increase in splenic IL‐10 mRNA levels was far greater
than that of splenic IL‐4 mRNA levels. Nonetheless, a significant increase in systemic mRNA lev‐
els to both Th2 cytokines was observed during MAIDS‐8 and MAIDS‐10, times during the course
of retrovirus‐induced immunosuppression when mice become susceptible to MCMV retinitis
following subretinal infection (Dix and Cousins, 2003a; Dix et al., 1994).
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Figure 3.1. IL‐4 and IL‐10 mRNA levels in whole splenic cells during progression of MAIDS. A.
IL‐4 mRNA levels in whole splenic cells during MAIDS progression versus healthy controls, p <
0.05 (n = 5) Error bars = Standard Error of Mean (SEM) of three independent experiments. As‐
terisks indicate statistical significance. B. IL‐10 mRNA levels in whole splenic cells during MAIDS
progression versus. healthy controls, p ≤ 0.03 (n = 5) Error bars = SEM of two independent ex‐
periments. Asterisks indicate statistical significance.
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3.2.2 Measurement of IL‐4 mRNA and protein levels in anti‐IL‐4 antibody treated MAIDS
mice
We first sought to determine if a reduction of IL‐4 during MAIDS would result in in‐
creased resistance to MCMV retinitis. Therefore, mice with MAIDS of 8‐weeks duration were
treated with either mouse anti‐IL‐4 IgG1 or matched isotype control IgG (i.p.) on days ‐3, 0, +3,
and +6 relative to subretinal injection of left eyes with MCMV (Atherton et al., 1991; Dix et al.,
1994) or subretinal mock‐injection of right eyes with maintenance media (control). On day 10
after subretinal injection, whole splenic cells were collected and quantified for IL‐4 mRNA or
protein levels using real‐time RT‐PCR assay or ELISA, respectively. Results are shown in the Fig‐
ure 3.2 A and B respectively. While anti‐IL‐4 antibody treatment protocol failed to reduce
splenic IL‐4 mRNA production in MAIDS animals, splenic IL‐4 protein levels were reduced by
~50%.

3.2.3 Measurement of IL‐10 mRNA levels in anti‐IL‐4 antibody treated MAIDS mice
We then wanted to confirm that reduction of IL‐4 through the use of anti‐IL‐4 antibody
would not affect the transcription of other Th2 cytokines. Thus, we quantified the mRNA ex‐
pression levels of the Th2 cytokine IL‐10 in whole splenic cells of anti‐IL‐4 antibody treated
MAIDS mice and matched MAIDS controls using real‐time RT‐PCR assay. Anti‐IL‐4 antibody
treatment of MAIDS mice did not alter IL‐10 mRNA levels when compared to control MAIDS
animals (Fig. 3.2C).
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Figure 3.2. IL‐4 mRNA, IL‐4 protein levels, and IL‐10 mRNA in whole splenic cells of anti‐IL‐4
antibody (Ab)‐treated MAIDS mice versus respective controls. A. IL‐4 mRNA levels in isotype‐
treated control vs. Ab‐treated p = 0.8053 (no statistical difference) (Wilcoxon Rank Sum test) (n
= 5 mice/group) Error bars = Standard Error of Mean (SEM) of two experiments. B. IL‐4 protein
levels of Ab‐treated vs. isotype‐treated control. p < 0.05 (Student T‐test) (n = 5 mice/group) Er‐
ror bar = Standard Deviation (SD) of two experiments. C. IL‐10 mRNA levels in Isotype‐treated
control vs. Ab‐treated p = 0.864 (no statistical difference) (Wilcoxon Rank Sum test) (n = 5
mice/group) Error bar = SEM of two independent experiments. Asterisks indicate statistical sig‐
nificance.
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3.2.4 Measurement of perforin, granzyme B and FasL mRNA levels in anti‐IL‐4 antibody
treated MAIDS mice
Since IL‐4 has been shown to inhibit perforin and granzyme B production and thereby
favor the Fas/FasL cytotoxic pathway (Aung and Graham, 2000; Baschuk et al., 2007; Dix et al.,
2003a; Kienzle et al., 2002; Kienzle et al., 2005), we next determined the fate of mRNAs for per‐
forin and granzyme B as well as FasL mRNA following systemic reduction of IL‐4 protein during
MAIDS‐related MCMV retinitis. Whole spleens were collected from anti‐IL‐4 antibody‐treated
MAIDS mice and matched control mice at day 10 after subretinal MCMV injection and quanti‐
fied for these mRNAs by real‐time RT‐PCR assay. We did not detect a significant difference in
perforin, granzyme B, or FasL mRNA production by splenic cells in anti‐IL‐4 antibody‐treated
mice with MAIDS when compared with splenic cells of control animals following subretinal
MCMV injection (Fig. 3.3 A, B, and C respectively).
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Figure 3.3. Perforin, Granzyme B, and FasL mRNA levels in whole splenic cells of anti‐IL‐4 an‐
tibody (Ab)‐treated MAIDS mice versus respective controls. A. Perforin mRNA levels in Iso‐
type‐treated control vs. Ab‐treated MAIDS splenic cells, p = 0.751 (no statistical difference)
(Wilcoxon Rank Sum test) (n = 5 mice/group) Error bar = SEM of two independent experiments.
B. Granzyme B mRNA levels in Isotype‐treated control vs. Ab‐treated MAIDS splenic cells, p =
0.105 (no statistical difference) (Wilcoxon Rank Sum test) (n = 5 mice/group) Error bar = SEM of
two independent experiments. C. FasL mRNA levels in Isotype‐treated control vs. Ab‐treated
MAIDS splenic cells, p = 0.695 (no statistical difference) (Wilcoxon Rank Sum test) (n = 5
mice/group) Error bar = SEM of two independent experiments. Asterisks indicate statistical sig‐
nificance.

60

3.2.5 Frequency and severity of MCMV Retinitis in anti‐IL‐4‐antibody treated MAIDS mice
We then sought to determine if reduction of IL‐4 levels during MAIDS resulted in in‐
creased resistance to MCMV retinitis. Ten days after subretinal MCMV infection, whole eyes of
anti‐IL‐4 antibody treated MAIDS mice and matched control MAIDS mice were collected and
analyzed for frequency and severity of retinitis. Results are shown in Table. 3.1 and Figure 3.4.
As expected, MCMV‐infected eyes of control mice with MAIDS exhibited a frequency of retinitis
of 83% (Dix and Cousins, 2004a), and with an average severity score of 2.84. In comparison,
MCMV‐infected eyes of anti‐IL‐4 antibody‐treated MAIDS animals remained susceptible to
MCMV retinitis. While the frequency of retinitis in MCMV‐infected eyes of mice with MAIDS
treated with neutralizing antibody to IL‐4 was reduced by ~30% and the severity of disease was
reduced to 2.35 when compared with control animals, these reductions were not significant.

Table 3.1. Frequency and severity of MCMV necrotizing retinitis in groups of mice with MAIDS
at day 10 after subretinal MCMV injection.
Group

Frequency of necrotizing

Severity Score

retinitis (retinitis/total)
MAIDS Isotype Control

83% (5/6)

2.84

MAIDS Anti‐IL‐4 Antibody

50% (3/6)

2.35

Treated
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Figure 3.4. Photomicrographs of anti‐IL‐4 antibody (Ab)‐treated MAIDS mice eyes and iso‐
type‐control mice eyes. Top panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen
sections of retina of mock‐infected eyes collected from control animals at 10 days following
subretinal injection of maintenance medium (right eyes) showing normal retinal architecture.
Bottom panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen sections of retina of
eyes at 10 days after subretinal MCMV injection (left eyes) showing full‐thickness retinal necro‐
sis. (hematoxylin & eosin; magnification X 200)
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3.2.6 Induction of MAIDS in mice deficient in IL‐4 or IL‐10
Due to the unexpected results obtained utilizing anti‐IL‐4 antibody treatment in MAIDS
mice, we employed a second experimental approach utilizing IL‐4 ‐/‐ and IL‐10 ‐/‐ to determine
if systemic reduction of IL‐4 or IL‐10 might lead to increased resistance to MCMV retinitis during
MAIDS as hypothesized. We first attempted to induce MAIDS in IL‐4 ‐/‐ mice and IL‐10 ‐/‐ mice.
Since IL‐4 and IL‐10 gene‐deficient mice are not available, we elected to use for these studies IL‐
4 ‐/‐ and IL‐10 ‐/‐ mice that possess a targeted mutation of the IL‐4 gene or IL‐10 gene that re‐
sults in the production of truncated, non‐functional IL‐4 (Kuhn et al., 1991) or IL‐10 (Kuhn et al.,
1993) protein products. Groups of IL‐4 ‐/‐ and IL‐10 ‐/‐ mice were therefore infected with the
immunosuppressive retrovirus mixture, LP‐BM5, housed for 8 weeks, and assessed for devel‐
opment of MAIDS using criteria established by us previously (Dix et al., 1994). All retrovirus‐
infected IL‐4 ‐/‐ and IL‐10 ‐/‐ mice exhibited physical and immunological features consistent
with development of MAIDS, and were designated as IL‐4 ‐/‐ MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐
8 mice.
Additional studies were performed to confirm that splenic IL‐10 mRNA levels were not
affected in IL‐4 ‐/‐ mice MAIDS‐8 following subretinal MCMV infection, and, conversely, splenic
IL‐4 mRNA levels were not affected in IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infec‐
tion. This was of interest since Green and coworkers (Green et al., 2008) noted that IL‐10 ‐/‐
mice infected with LP‐BM5 exhibited exaggerated disease development when compared with
wild‐type LP‐BM5‐infected C57BL/6 mice, an outcome that might affect splenic IL‐4 mRNA pro‐
duction. Results are shown in Fig. 3.4. While equivalent amounts of IL‐10 mRNA levels were ob‐
served in splenic cells collected from wild‐type MAIDS‐8 mice and IL‐4 ‐/‐ MAIDS‐8 mice follow‐
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ing intraocular MCMV infection, IL‐10 protein levels were significantly increased in IL‐4‐/‐
MAIDS‐8 mice. In comparison, while splenic IL‐4 mRNA levels were reduced by ~50% in IL‐10 ‐/‐
MAIDS‐8 mice when compared with wild‐type MAIDS‐8 mice following intraocular MCMV infec‐
tion, nearly equivalent amounts of IL‐4 protein were found within splenic cells of both animal
groups.
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Figure 3.5. IL‐10 mRNA and IL‐10 protein levels in whole splenic cells of IL‐4 ‐/‐ MAIDS‐8 mice
versus respective controls and IL‐4 mRNA and IL‐4 protein levels in whole splenic cells of IL‐10
‐/‐ MAIDS‐8 mice versus respective controls. A. IL‐10 mRNA levels in whole splenic cells wild‐
type MAIDS versus IL‐4‐/‐ MAIDS‐8 mice, p = 0.432 (n = 10) Error bars = SEM of two independ‐
ent experiments. B. IL‐10 protein levels in whole splenic cells of wild‐type MAIDS vs. IL‐4‐/‐
MAIDS‐8 mice, p ≤ 0.02 (n = 10) Error bars = Standard Deviation (SD) of two independent ex‐
periments. Asterisks indicate statistical significance. C. IL‐4 mRNA in whole splenic cells of wild‐
type MAIDS versus IL‐10‐/‐ MAIDS‐8 mice, p ≤ 0.04 (n = 5) Error bars = SEM of one experiment.
Asterisks indicate statistical significance. D. IL‐4 protein in whole splenic cells of wild‐type
MAIDS versus IL‐10‐/‐ MAIDS‐8 mice p = 0.939 (n = 8, wild‐type MAIDS‐8 mice; n = 10, IL‐10‐/‐
MAIDS‐8 mice) Error bars = SD of one experiment.
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3.2.7 Quantification of amounts of infectious MCMV within eyes of wildtype MAIDS‐8 mice,
IL‐4 ‐/‐ MAIDS‐8 mice, and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection
We have shown previously that the amounts of infectious MCMV within the ocular
compartments of mice with MAIDS increase remarkably during development of retinitis follow‐
ing subretinal MCMV injection (Dix and Cousins, 2003a; Dix and Cousins, 2004a; Dix et al.,
1994). Moreover, since increased IL‐4 and IL‐10 production would tend to delay virus clearance
by dampening of CD8+ T‐cell cytotoxicity, we sought to determine if loss of IL‐4 or IL‐10 would
affect virus replication during MAIDS. Eyes of IL‐4 ‐/‐ MAIDS‐8 mice, IL‐10 ‐/‐ mice, and wild‐
type MAIDS mice were therefore infected with MCMV by subretinal injection, collected 10 days
later, and subjected to standard plaque assay for quantification and comparison of amounts of
infectious virus. As shown in Fig. 3.5, equivalent amounts of infectious virus were found in
MCMV‐infected eyes of IL‐4 ‐/‐ MAIDS‐8 mice, IL‐10 ‐/‐ MAIDS‐8 mice, and their respective wild‐
type MAIDS‐8 controls. Thus, systemic loss of IL‐4 or IL‐10 during MAIDS did not appear to im‐
pact virus replication significantly within the eye, either positively or negatively.
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Figure 3.6. Ocular MCMV titer in wild‐type MAIDS‐8 mice, IL4 ‐/‐ MAIDS‐8 mice, and IL‐10 ‐/‐
MAIDS‐8 mice. A. Average virus titer (expressed as PFU/eye/ml) in whole eyes of wild‐type
MAIDS‐8 mice versus IL‐4‐/‐ MAIDS‐8 mice at 10 days after subretinal MCMV infection p = 0.658
(n = 5) Error bars = SEM of one experiment. B. Average virus titer (expressed as PFU/eye/ml) in
whole eyes of wild‐type MAIDS‐8 mice versus IL‐10 ‐/‐ MAIDS‐8 mice at 10 days after subretinal
MCMV infection p = 0.800 (n = 4) Error bars = SEM of one experiment.
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3.2.8 Frequency and severity of MCMV retinitis in IL‐4 ‐/‐ MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐
8 mice following subretinal MCMV infection
Since systemic loss of IL‐4 or IL‐10 had no effect of the amount of virus within the eyes of
MAIDS‐8 mice that have been shown previously by us to be susceptible to retinitis (Dix and
Cousins, 2004a; Dix et al., 1994), we sought to determine whether systemic loss of IL‐4 or IL‐10
would result in increased resistance to retinitis as hypothesized. In separate experiments, IL‐4 ‐
/‐ MAIDS‐8 mice, IL‐10 ‐/‐ MAIDS‐8 mice, and their respective wild‐type MAIDS‐8 controls were
infected with MCMV by subretinal inoculation. Ten days later, all eyes were collected, analyzed
histopathologically, and scored for frequency and severity of necrotizing retinitis using a scoring
system described previously (Dix et al., 1994). Results are shown in Table 3.2, Figure 3.6, and
Figure 3.7. As expected, MCMV‐infected eyes of wild‐type MAIDS‐8 control mice were indeed
susceptible to retinitis as indicated by frequencies of retinitis of 78% and 100% in separate ex‐
periments (average = 89%). In sharp opposition to our hypothesis, however, MCMV‐infected
eyes collected from IL‐4 ‐/‐ MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 exhibited a frequency of retini‐
tis equivalent to that observed in control animals. Whereas 89% of MCMV‐infected eyes of IL‐4
‐/‐ MAIDS‐8 mice showed retinitis, 85% of IL‐10 ‐/‐ MAIDS‐8 mice also showed retinitis. Al‐
though frequency of retinitis was unaffected in MAIDS animals with a systemic loss of IL‐4 or IL‐
10, it was possible that loss of these Th2 cytokines would result in a decrease in severity of reti‐
nal disease. This was not the case (Table 3.2). When scored for severity of retinitis (Dix et al.,
1994), a statistical difference was not observed when MCMV‐infected eyes of IL‐4 ‐/‐ MAIDS‐8
mice or MCMV‐infected eyes of IL‐10 ‐/‐ MAIDS‐8 mice were compared with MCMV‐infected
eyes of their respective controls.
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Table 3.2. Frequency and severity of MCMV necrotizing retinitis in wild‐type MAIDS‐8 mice,
IL‐4‐/‐ MAIDS‐8 mice, and IL‐10‐/‐ MAIDS‐8 mice at day 10 after subretinal MCMV infection.
Group

Frequency of

Severity Score

Necrotizing retinitis
(retinitis/total)
Wildtype MAIDS‐8

78% (7/9)

2.94 (n = 7)

IL‐4 ‐/‐ MAIDS‐8

89% (8/9)

3.24 (n = 8)

Wildtype MAIDS‐8

100% (4/4)

3.72 (n = 4)

IL‐10 ‐/‐ MAIDS‐8

85% (6/7)

3.14 (n = 6)
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Figure 3.7. Photomicrographs of IL‐4 ‐/‐ MAIDS mice eyes and wild‐type MAIDS mice eyes.
Top panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen sections of retina of
mock‐infected eyes collected from control animals at 10 days following subretinal injection of
maintenance medium (right eyes) showing normal retinal architecture. Bottom panel: Photomi‐
crographs of formalin‐fixed OCT‐embedded frozen sections of retina of eyes at 10 days after
subretinal MCMV injection (left eyes) showing full‐thickness retinal necrosis. (hematoxylin &
eosin; magnification X 200)
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Figure 3.8. Photomicrographs of IL‐10 ‐/‐ MAIDS mice eyes and wild‐type MAIDS mice eyes.
Top panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen sections of retina of
mock‐infected eyes collected from control animals at 10 days following subretinal injection of
maintenance medium (right eyes) showing normal retinal architecture. Bottom panel: Photomi‐
crographs of formalin‐fixed OCT‐embedded frozen sections of retina of eyes at 10 days after
subretinal MCMV injection (left eyes) showing full‐thickness retinal necrosis. (hematoxylin &
eosin; magnification X 200)
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3.2.9 Quantification of splenic perforin, granzyme B, and FasL mRNA levels in IL‐4 ‐/‐ MAIDS‐
8 mice and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection
Since MCMV‐infected eyes of mice with MAIDS deficient in systemic IL‐4 or IL‐10 failed to show
a decrease in frequency or severity of retinitis as predicted, we were interested in knowing the
fate of mRNAs of key molecules involved in CD8+ T‐cell cytotoxicity in animals unable to pro‐
duce functional systemic IL‐4 or IL‐10. These included perforin and granzyme B mRNAs associ‐
ated with the perforin cytotoxic pathway (Paul, 2008) and FasL mRNA associated with the
Fas/FasL cytotoxic pathway (Paul, 2008). This was accomplished by measurement of perforin,
granzyme B, and FasL mRNAs originating from splenic cells collected from IL‐4 ‐/‐ MAIDS‐8 mice
and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection and comparing these amounts
by quantitative RT‐PCR assay with those obtained from wild‐type MAIDS‐8 mice following
subretinal MCMV infection. As shown in Fig. 3.8, amounts of splenic perforin and granzyme B
mRNAs remained relatively unchanged in mice with MAIDS deficient in systemic IL‐4 or IL‐10
production when compared with wild‐type MAIDS animals. Moreover, MAIDS mice deficient in
systemic IL‐4 or IL‐10 production showed a significant increase in splenic FasL mRNA produc‐
tion, an unexpected finding.
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Figure 3.9. Perforin, granzyme B, and FasL mRNA levels in whole splenic cells of IL‐4 ‐/‐
MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 mice versus respective controls. A. Perforin mRNA levels
in splenic cells of wild‐type MAIDS‐8 mice versus IL‐4‐/‐ MAIDS‐8 mice; p = 0.780 (n = 5) Error
bars = SEM of two independent experiments. B. Perforin mRNA levels in splenic cells of wild‐
type MAIDS‐8 mice versus IL‐10‐/‐ MAIDS‐8 mice; p = 0.49 (n = 5) Error bars = SEM on one ex‐
periment. C. Granzyme B mRNA levels in splenic cells of wild‐type MAIDS‐8 mice versus IL‐4‐/‐
MAIDS‐8 mice; p = 0.691 (n = 5) Error bars = SEM of two independent experiments. D. Gran‐
zyme B mRNA levels in splenic cells of wild‐type MAIDS‐8 versus IL‐10 ‐/‐ MAIDS‐8 mice; p =
0.22 (n = 5) Error bars = SEM of one experiment. E. FasL mRNA in splenic cells of wild‐type
MAIDS‐8 mice versus IL‐4 ‐/‐ MAIDS‐8 mice; p ≤ 0.01 (n = 5) Error bars = SEM of two independ‐
ent experiments. F. FasL mRNA in splenic cells of wild‐type MAIDS‐8 mice versus IL‐10 ‐/‐
MAIDS‐8 mice; p ≤ 0.007 (n = 5) Error bars = SEM of one experiment. Asterisks indicate statisti‐
cal significance.
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4

AIM 2: TEST THE HYPOTHESIS THAT INCREASED PRODUCTION OF IL‐17 FROM CD4+ TH17
CELLS CONTRIBUTES TO THE PATHOGENESIS OF EXPERIMENTAL MCMV RETINITIS IN MICE
WITH MAIDS

4.1

Introduction
A more recently recognized CD4+ Th cell subset, Th17 cells, secretes a unique set of cyto‐

kines that includes IL‐17A (IL‐17) as well as TNF‐α, IL‐22, and IL‐6 (Annunziato et al., 2010;
Bettelli et al., 2007; Furuzawa‐Carballeda et al., 2007; Schmidt‐Weber et al., 2007). Differentia‐
tion of the Th17 linage is dependent upon the secretion of IL‐6 and TFG‐ß from APCs (Bettelli et
al., 2007; Furuzawa‐Carballeda et al., 2007; Gaffen, 2009; Schmidt‐Weber et al., 2007); the
Th17 lineage is stabilized by IL‐23 secretion from APCs (Bettelli et al., 2007; Furuzawa‐
Carballeda et al., 2007; Gaffen, 2009; Schmidt‐Weber et al., 2007). A pro‐inflammatory cyto‐
kine, IL‐17 functions by binding to its receptor, IL‐17RA, that is expressed on a wide range of
cells (Annunziato et al., 2010; Weaver et al., 2007) and thereby stimulates a number of immune
responses including the recruitment of macrophages and neutrophils (Annunziato et al., 2010;
Stockinger et al., 2007; Weaver et al., 2007). Of significance, however, is that IL‐17 has been
associated with cellular damage that occurs during autoimmune diseases including rheumatoid
arthritis and multiple sclerosis (Annunziato et al., 2010; Furuzawa‐Carballeda et al., 2007; Korn
et al., 2009; Lovett‐Racke et al., 2011). Recent work by Luger and colleagues (Luger and Caspi,
2008; Luger et al., 2008) and others (Amadi‐Obi et al., 2007; Caspi, 2008; Peng et al., 2007) has
also linked IL‐17 to uveitis, a leading cause of blindness in the United States (Caspi, 2010).
Although Th17 cells have been implicated in the pathogenesis of various autoimmune
diseases, the role of IL‐17 during HIV‐induced immunosuppression remains controversial.
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Brenchley and co‐workers (Brenchley et al., 2008) found that Th17 cells were lost in mucosa of
the gastrointestinal tract of HIV‐infected patients, but remained intact in simian immunodefi‐
ciency virus‐infected sooty mangabey monkeys. In contrast, other studies have found that IL‐17
secretion from Th17 cells was increased during HIV infection (Maek et al., 2007; Yue et al.,
2008). To more clearly elucidate the role of Th17 cells in HIV infection as well as the potential
contribution(s) of IL‐17 to the pathogenesis of AIDS‐related HCMV retinitis, we performed a se‐
ries of studies to test the hypotheses that systemic IL‐17 is increased during retrovirus‐induced
immunosuppression, and this systemic increase in IL‐17 production plays a role in the patho‐
genesis of cytomegalovirus retinitis within the ocular compartment.
These hypotheses were tested using a mouse model of MCMV retinitis that develops in
mice with MAIDS, a retrovirus‐induced immunodeficiency syndrome with features that closely
mimic HIV/AIDS in humans (Dix and Cousins). Importantly, mice with MAIDS exhibit lymphade‐
nopathy, polyclonal B‐cell activation, hypergammaglobulinemia, and a retrovirus‐induced shift
in cytokine production from a dominant Th1 response to a dominant Th2 response prior to sus‐
ceptibility to experimental MCMV retinitis (Dix and Cousins, 2004a; Dix et al., 1994; Morse et
al., 1995), thereby making this an attractive animal model to investigate IL‐17 in the context of
MCMV retinal disease development.
We report herein that while IL‐17 mRNA and protein levels increased in mice with MAIDS,
CD4+ T cells were not the sole source of IL‐17 during retrovirus‐induced immunosuppression
progression. Surprisingly, however, IL‐17 mRNA and protein levels were dampened in MCMV‐
infected eyes of mice with MAIDS that were susceptible to retinitis, a result that was also ob‐
served following systemic MCMV infection of both healthy mice and MAIDS mice. Decreased
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levels of IL‐17 correlated with increased mRNA levels of IL‐10 and suppressor of cytokine signal‐
ing (SOCS)‐3 during MCMV infection. While systemic MCMV infection of healthy IL‐10 ‐/‐ mice
resulted in a partial recovery of IL‐17 protein levels, IL‐10 ‐/‐ MAIDS animals remained suscepti‐
ble to MCMV retinitis at levels equivalent to wild‐type MAIDS mice. Taken together, our results
suggest that IL‐17 plays no direct role in the pathogenesis of MAIDS‐related MCMV retinitis, but
that MCMV downregulates IL‐17 from CD4+ T cells through the upregulation of IL‐10 and po‐
tentially SOCS‐3.
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4.2

Results

4.2.1 IL‐17 protein production in whole splenic cells and whole eyes of healthy C57BL/6 mice
We first sought to determine baseline levels of expression of IL‐17 protein in the spleens
and eyes of C57BL/6 mice during health. Results are shown in Figure 1. Detectable amounts of
IL‐17 protein were found in homogenates of whole splenic cells and whole eyes of healthy ani‐
mals by ELISA (Fig. 4.1A and Fig. 4.1B) as well as by Western blot analysis (data not shown).
ELISA showed 4.73 + 1.84 pg of IL‐17 per gram of spleen (wet weight) and 0.87 + 0.31 pg of IL‐
17 per whole eye. Moreover, visualization of IL‐17 protein by immunohistochemical staining of
the posterior segment of healthy whole eyes revealed constitutive expression of IL‐17 with an
expression pattern confined to the photoreceptor and inner plexiform layers of the neurosen‐
sory retina (Fig. 4.1C). Thus, IL‐17 was not only produced within the spleen of healthy mice, but
was also found to be expressed constitutively by cells of the neurosensory retina of healthy
mice. Further analysis of the photoreceptor cells revealed that both rods and cones constitu‐
tively express IL‐17 during health (Fig 4.2).
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Figure 4.1. Detection and quantification of IL‐17 protein in whole splenic cells and whole eyes
of healthy C57Bl/6 mice. (A) IL‐17 protein in whole splenic cells of adult healthy C57BL/6 mice
as determined by ELISA [pg of IL‐17 per gram of spleen (wet weight] (n = 10). Bars = Standard
Deviation of 1 experiment. (B) IL‐17 protein in whole eyes of adult healthy C57BL/6 mice as de‐
termined by ELISA [pg of IL‐17 per whole eyes] (n = 10). Bars = Standard Deviation of 1 experi‐
ment. (C) Detection of IL‐17 in cells of a representative retinal tissue section collected from an
adult healthy mouse. Formalin‐fixed cytosections were reacted with anti‐IL‐17 antibody (red) or
an isotype‐matched normal antibody (control). Nuclei were counterstained with DAPI (blue)
(200X).
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Figure 4.2. Detection of IL‐17 protein in photoreceptor cells of healthy C57BL/6 mice. Forma‐
lin‐fixed cytosections were reacted with anti‐IL‐17 antibody (red) and anti‐OpsinSW antibody
(green) or anti‐Rhodopsin antibody (green). Nuclei were counterstained with DAPI (blue)
(400X).
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4.2.2 IL‐17 mRNA and protein production in whole splenic cells and whole eyes of C57BL/6
mice during progression of MAIDS
After establishing baseline levels of expression of IL‐17 in the spleen and eyes of healthy
C57BL/6 mice, we next investigated possible changes in IL‐17 mRNA and protein production
during the progression of MAIDS in order to clarify the fate of IL‐17 during retrovirus‐
immunosuppression. Whole splenic cells and whole eyes were collected from MAIDS‐4, MAIDS‐
8, and MAIDS‐10 mice and quantified for IL‐17 mRNA and protein levels by real‐time RT‐PCR
assay and ELISA, respectively. Progression of MAIDS was associated with a significant (p ≤ 0.03)
increase in IL‐17 mRNA levels in whole splenic cells, with the levels peaking in MAIDS‐10 ani‐
mals (Fig. 4.3A). This increase in IL‐17 transcript production was reflected in a significant (p ≤
0.001) increase in IL‐17 protein production in whole splenic cells during MAIDS progression,
with protein levels being highest at 41.5 ± 6.1 and 23.5 ± 5.13 pg per gram of spleen (wet
weight) in MAIDS‐8 and MAIDS‐10 animals, respectively (Fig. 4.3B).
MAIDS progression was also associated with a significant (p ≤ 0.0006) increase in IL‐17
mRNA levels in whole eyes of MAIDS‐8 and MAIDS‐10 animals (Fig. 4.3C), but ocular IL‐17 pro‐
tein levels in these animals did not differ from IL‐17 levels in the eyes of healthy mice (Figure
4.3D). We postulate that this is due to the degradation of IL‐17 mRNA shortly after transcription
or the storage of IL‐17 mRNA in cytoplasmic vesicles such that mRNA is ultimately not being
translated into protein. It is noteworthy that previous work has shown MAIDS‐8 and MAIDS‐10
animals are susceptible to MCMV retinitis (Dix and Cousins, 2004a; Dix et al., 1994). The ele‐
vated levels of IL‐17 mRNA and protein in whole splenic cells during the progression of MAIDS
suggested that numbers of IL‐17‐producing Th17 cells may be increased during progression of
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retrovirus‐induced immunosuppression, but this increase may not necessarily be found within
the ocular compartment.

Figure 4.3. IL‐17 mRNA and protein levels in whole splenic cells and whole eyes of C57BL/6
mice during the progression of MAIDS. Comparison of (A) IL‐17 mRNA levels of whole splenic
cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5), and (C) IL‐17
mRNA levels of whole eyes collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n
= 5). Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars =
Standard Error of the Mean of 3 independent experiments. Asterisks indicate statistical signifi‐
cance. Comparison of (B) IL‐17 protein levels of whole splenic cells collected from groups of
MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5), and (D) IL‐17 protein levels of whole eyes col‐
lected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5). Levels (fold‐change) of IL‐
17 mRNA were determined by quantitative RT‐PCR assay. Protein levels were determined by
ELISA. Bars = Standard Deviation of 1 experiment.
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4.2.3 IL‐17 mRNA levels in enriched populations of splenic CD4+ T cells, splenic macro‐
phages, and splenic Gr‐1‐expressing cells (neutrophils) during progression of MAIDS
We next sought to determine the cellular source of splenic IL‐17 production in MAIDS‐8
and MAIDS‐10 animals. Known cellular sources of IL‐17 that included populations of splenic
CD4+ T cells, splenic macrophages, and splenic Gr‐1‐expressing cells (neutrophils) (Gu et al.,
2008; Korn et al., 2009; Weaver et al., 2007) were enriched by flow cytometry (purity > 90%)
from the whole spleens of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice and quantified for IL‐17
mRNA levels by real‐time RT‐PCR assay. Unlike whole splenic cells, the progression of MAIDS
was associated with a decrease in IL‐17 mRNA levels in splenic cells enriched for CD4+ T cells
(Fig. 4.4). Purified splenic macrophages and splenic Gr‐1‐expressing cells (neutrophils) also ex‐
hibited similar yet significant (p ≤ 0.05) decreases in IL‐17 mRNA levels, and therefore contrib‐
uted little to overall expression of IL‐17 mRNA within the whole spleen (Fig. 4.4). Our finding of
decreased IL‐17 mRNA from CD4+ T cells during MAIDS progression suggested that retrovirus‐
induced immunosuppression might alter essential Th17 cell differentiation factors including IL‐
23 and IL‐6.
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Figure 4.4. IL‐17 mRNA levels of enriched populations of splenic CD4+ T cells, splenic macro‐
phages, and splenic Gr‐1+ cells (neutrophils) from C57BL/6 mice during the progression of
MAIDS. IL‐17 mRNA levels for enriched populations (> 90% purity) of splenic CD4+ T cells (gray
bars), splenic macrophages (black bars), and splenic Gr‐1+ cells (neutrophils) (white bars) of
whole splenic cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5).
Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = Stan‐
dard Error of the Mean of 3 independent experiments. Asterisks indicate statistical significance.
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4.2.4 IL‐6 and IL‐23 mRNA production in whole splenic cells during progression of MAIDS
IL‐6 and IL‐23 from APCs are required for the differentiation of the mouse Th17 lineage
(Bettelli et al., 2007; Furuzawa‐Carballeda et al., 2007; Gaffen, 2009; Schmidt‐Weber et al.,
2007). In order to address the discrepancy that was seen in IL‐17 mRNA expression levels be‐
tween whole splenic cells and purified populations of splenic CD4+ T cells during MAIDS pro‐
gression, we measured IL‐6 and IL‐23 mRNA levels in order to determine whether these cytoki‐
nes were reduced at various times during retrovirus‐induced immunosuppression. Whole
splenic cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice exhibited IL‐6 and
IL‐23 mRNA levels equivalent to mRNA levels seen in healthy age‐matched control mice (Fig.
4.5). Thus, the decrease in IL‐17 mRNA production seen in CD4+ T cells during MAIDS progres‐
sion was not due to the unavailability of the essential linage factors IL‐6 or IL‐23. Our findings
suggest that in addition to splenic CD4+ T cells, other cellular sources like CD8+ T cells or NKT
cells contribute to the overall increase in IL‐17 production in whole splenic cells during MAIDS
progression (Kondo et al., 2009; Rachitskaya et al., 2008).
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Figure 4.5. IL‐6 and IL‐23 mRNA levels of whole splenic cells from C57BL/6 mice during the
progression of MAIDS. IL‐6 and IL‐23 mRNA levels of whole splenic cells collected from groups
of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5). Levels (fold‐change) of IL‐6 and IL‐23 mRNA
were determined by quantitative RT‐PCR assay. Bars = Standard Error of the Mean of 3 inde‐
pendent experiments. Asterisks indicate statistical significance.
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4.2.5 IL‐17 mRNA levels in MCMV‐infected eyes of MAIDS‐4 mice resistant to retinitis and
MCMV‐infected eyes of MAIDS‐10 mice susceptible to retinitis
We next sought to determine whether the increased systemic levels of IL‐17 from whole
splenic cells of MAIDS mice contributed to the pathogenesis of MCMV‐related retinitis. We
have previously reported that while MCMV‐infected eyes of MAIDS‐4 and MCMV‐infected eyes
of MAIDS‐10 mice have equivalent amounts of infectious virus at 10 days after subretinal
MCMV infection, MAIDS‐4 animals are resistant to MCMV retinitis whereas MAIDS‐10 animals
are susceptible to MCMV retinitis (Chien and Dix, 2012; Dix and Cousins, 2004b). Because
MAIDS‐4 and MAIDS‐10 mice exhibit such divergent pathogenic outcomes following subretinal
MCMV infection, we compared MCMV‐infected eyes of MAIDS‐4 and MCMV‐infected eyes of
MAIDS‐10 mice for amounts of IL‐17 mRNA. Whole eyes were collected from parallel groups of
MAIDS‐4 and MAIDS‐10 animals inoculated subretinally with MCMV or maintenance medium
only (control), and analyzed on days 3, 6, and 10 post‐infection for amounts of IL‐17 mRNA.
Subretinal MCMV infection of eyes of MAIDS‐4 mice did not result in increased IL‐17 mRNA lev‐
els when compared to mock‐infected eyes of MAIDS‐4 mice (Fig. 4.6A). In sharp contrast,
MCMV‐infected eyes of MAIDS‐10 mice exhibited a significant (p ≤ 0.05) decrease in IL‐17
mRNA levels on day 10 when compared to mock‐infected eyes of MAIDS‐10 mice (Fig. 4.6A).
Due to the significant decrease in IL‐17 mRNA levels in MCMV‐infected eyes of MAIDS‐
10 mice, ELISA and immunohistochemical staining were also utilized to detect and quantify in‐
traocular IL‐17 protein in these animals. IL‐17 protein levels were decreased, although not sig‐
nificantly, when compared to contralateral mock‐infected eyes (data not shown). Immunohis‐
tochemical staining also revealed that IL‐17 protein was detectable in cells of the neurosensory
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retina and RPE of the eyes of both MCMV‐infected and mock‐infected MAIDS‐10 mice (Fig
4.6B), but IL‐17 production in the MCMV‐infected eyes of MAIDS‐10 mice was dampened when
compared to mock‐infected eyes. Taken together (Fig 4.6A and 4.6B), these unexpected results
suggested that MCMV infection may downregulate IL‐17 production within the ocular com‐
partment during MAIDS.
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Figure 4.6. IL‐17 mRNA levels in MCMV‐infected eyes of MAIDS‐4 versus MAIDS‐10 mice and
detection of IL‐17 protein in MCMV‐infected eyes of MAIDS‐10 mice. A) Comparison of IL‐17
mRNA levels in MCMV‐infected eyes of MAIDS‐4 mice (blue dashed line) versus MCMV‐infected
eyes of MAIDS‐10 mice (red solid line) collected at 3, 6, or 10 days after subretinal MCMV infec‐
tion (n = 5). Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay.
Bars = Standard Error of the Mean of 2 independent experiments. Asterisks indicate statistical
significance. (B) Detection of IL‐17 in cells of representative retinal tissue sections collected
from eyes of MAIDS‐10 mice at 10 days after subretinal MCMV infection or mock infection.
Formalin‐fixed cytosections were reacted with anti‐IL‐17 antibody (red) or an isotype‐matched
normal antibody (control). Nuclei were counterstained with DAPI (blue) (200X).
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4.2.6 Effect of systemic MCMV infection on IL‐17 mRNA levels in splenic CD4+ T cells during
health and MAIDS
The observation of significantly decreased IL‐17 mRNA levels and dampened protein
levels in MCMV‐infected eyes of MAIDS‐10 mice led us to investigate the remarkable possibility
that MCMV infection might lead to a preferential downregulation of IL‐17 from CD4+ Th17 cells
systemically. To investigate this possibility, IL‐17 mRNA levels were quantified by real‐time RT‐
PCR assay in populations of splenic CD4+ T cells enriched by flow cytometry (purity > 90%) from
groups of healthy, MAIDS‐4, or and MAIDS‐10 mice infected systemically by i.p. injection with a
sublethal dose of MCMV for 6 days. Systemic MCMV infection of all animals resulted in a sig‐
nificant (p ≤ 0.01) decrease in IL‐17 mRNA levels in splenic CD4+ T cells when compared to
mock‐infected controls (Figs. 4.7A and 4.7B). Whole splenic cell populations from all animal
groups also exhibited a significant (p ≤ 0.008) decrease in IL‐17 mRNA levels (data not shown).
Thus, systemic MCMV infection did indeed result in a significant downregulation of IL‐17 mRNA
production from CD4+ T cells.
In order to determine whether productive MCMV infection was required to downregu‐
late IL‐17 mRNA production in CD4+ T cells, groups of healthy, MAIDS‐4, or MAIDS‐10 mice
were systemically inoculated with either UV‐inactivated MCMV or infectious MCMV for 6 days,
and splenic CD4+ T cells enriched by flow cytometry (purity >90%) were analyzed for IL‐17
mRNA expression via real‐time RT‐PCR assay. IL‐17 mRNA levels were significantly (p ≤ 0.05) re‐
duced in all animals inoculated with UV‐inactivated MCMV (Fig. 4.7C), but IL‐17 mRNA levels
were further reduced when animals were inoculated with infectious MCMV (Fig. 4.7C). These
results suggest that MCMV structural protein(s) (tegument proteins and/or glycoproteins) as
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well as one or more virus‐induced proteins produced during active virus replication alter the
host cell response to decrease IL‐17 production during systemic MCMV infection.

Figure 4.7. IL‐17 mRNA levels in splenic CD4+ T cells of healthy C57BL/6 mice, MAIDS‐4 mice,
and MAIDS‐10 mice following systemic MCMV infection. IL‐17 mRNA levels of splenic CD4+ T
cells collected from (A) groups of healthy C57BL/6 mice (n = 5) and (B) groups of MAIDS‐4 and
MAIDS‐10 mice (n = 5) at 6 days after i.p. inoculation with MCMV or mock‐infection. Levels
(fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = Standard
Error of the Mean of 3 independent experiments. Asterisks indicate statistical significance. (C)
IL‐17 mRNA levels of splenic CD4+ T cells collected from MAIDS‐4 mice, MAIDS‐10 mice, and
their age‐matched healthy controls inoculated with either UV‐inactivated MCMV or infectious
MCMV. Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars
= Standard Error of the Mean of 1 experiment. Asterisks indicate statistical significance.
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4.2.7 SOCS‐3, SOCS‐1, and IL‐10 mRNA expression levels in whole splenic cells of mice with
MAIDS.
We then sought to investigate the possible mechanism(s) by which IL‐17 mRNA was be‐
ing downregulated by CD4+ T cells during MAIDS progression and ultimately during MCMV in‐
fection. Previous studies conducted by Chen and colleagues (Chen et al., 2006) identified the
SOCS‐3 protein as a negative regulator of IL‐17 in CD4+ T cells. Additionally, loss of the SOCS‐1
protein leads to defective Th17 cell differentiation (Tanaka et al., 2008; Yoshimura et al., 2007).
Ongoing work in our laboratory by Dr. Hsin Chien has also tied SOCS‐1 and SOCS‐3 to MCMV‐
related disease. Although both SOCS‐1 and SOCS‐3 are increased during HIV infection (Akhtar
and Benveniste, 2011), we investigated whether SOCS‐3 mRNA levels were increased in mice
with retrovirus‐induced immunosuppression and/or whether SOCS‐1 mRNA levels were de‐
creased, thereby leading to a decrease in IL‐17 expression from CD4+ T cells during MAIDS.
Whole splenic cells collected from groups of MAIDS‐4, MAIDS‐8, or MAIDS‐10 mice were quan‐
tified for SOCS‐1 and SOCS‐3 mRNA levels by real‐time RT‐PCR assay. Whereas splenic mRNA
levels of SOCS‐1 in MAIDS animals remained equivalent to mRNA levels of healthy mice (Fig.
4.8A), SOCS‐3 mRNA levels were significantly (p ≤ 0.05) increased during MAIDS progression
(Fig. 4.8B). Importantly, increased SOCS‐3 mRNA levels correlated with decreased IL‐17 mRNA
levels in splenic CD4+ T cells seen during MAIDS progression (Fig. 4.4).
Recent work has also led to the identification of the IL‐10R on the surface of Th17 cells
(Huber et al., 2011); IL‐10 is able to bind its receptor and negatively regulate the secretion of IL‐
17 from Th17 cells (Chaudhry et al., 2011). We therefore sought to determine if IL‐10 mRNA
expression during MAIDS progression was also increased. Whole splenic cells collected from
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groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice exhibited a significant (p ≤ 0.03) increase in
IL‐10 mRNA production (Fig. 4.8C). In particular, levels of IL‐10 mRNA were high in whole
splenic cells of MCMV retinitis‐susceptible MAIDS‐8 and MAIDS‐10 animals (Dix and Cousins,
2004a; Dix et al., 1994). The increase in IL‐10 mRNA levels in whole splenic cells of MAIDS‐8
mice and MAIDS‐10 mice correlated with the decrease in IL‐17 mRNA levels seen in CD4+ T cells
during MAIDS progression (Fig. 4.4).
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Figure 4.8. SOCS‐1, SOCS‐3, and IL‐10 mRNA levels in whole splenic cells of C57BL/6 mice dur‐
ing the progression of MAIDS. (A) SOCS‐1 mRNA levels, (B) SOCS‐3 mRNA levels, and (C) IL‐10
mRNA levels of whole splenic cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10
mice (n = 5). Levels (fold‐change) of SOCS‐1 mRNA, SOCS‐3 mRNA, and IL‐10 mRNA were de‐
termined by quantitative RT‐PCR assay. Bars = Standard Error of the Mean of 2 independent
experiments. Asterisks indicate statistical significance.
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4.2.8 SOCS‐1, SOCS‐3, and IL‐10 mRNA levels in MCMV‐infected eyes of MAIDS‐4 mice resis‐
tant to retinitis and MCMV‐infected eyes of MAIDS‐10 mice susceptible to retinitis
To determine whether SOCS‐3 and IL‐10 production were also negatively influencing the
expression of IL‐17 during the onset and progression of retinal necrosis in the eyes of MAIDS
mice, MCMV‐infected and mock‐infected eyes from MAIDS‐4 and MAIDS‐10 mice were col‐
lected on days 3, 6, and 10 after MCMV subretinal infection and analyzed for SOCS‐3 and IL‐10
mRNA expression. Additionally, mRNA levels of the required Th17 lineage differentiation factors
SOCS‐1 and IL‐6 (Bettelli et al., 2007; Yoshimura et al., 2007) were also examined in MCMV‐
infected and mock‐infected eyes of MAIDS‐4 and MAIDS‐10 mice. While SOCS‐3 mRNA levels
were indeed significantly (p ≤ 0.03) increased in MCMV‐infected eyes of MAIDS‐4 mice on day 6
prior to the appearance of retinal necrosis on day 10 (Chien and Dix, 2012; Dix et al., 1994),
MCMV‐infected eyes of MAIDS‐10 mice exhibited a far greater increase (p ≤ 0.007) in SOCS‐3
mRNA levels when compared with mRNA levels of MCMV‐infected eyes of MAIDS‐4 mice on
day 6 post‐infection (Fig. 4.9B). Similarly, IL‐10 mRNA levels in MCMV‐infected eyes of MAIDS‐
10 mice exhibited a dramatic 12‐fold and ~60‐fold (p ≤ 0.01) increase in IL‐10 mRNA on days 3
and 6 post‐infection, respectively, when compared with mRNA levels in MCMV‐infected eyes of
MAIDS‐4 mice (Fig. 4.9C). In comparison, SOCS‐1 (Fig. 4.9A) and IL‐6 (data not shown) mRNA
levels mirrored those seen for SOCS‐3 and IL‐10, with mRNA levels of both molecules being sig‐
nificantly (p ≤ 0.03) increased in MCMV‐infected eyes of MAIDS‐10 mice when compared to
MCMV‐infected eyes of MAIDS‐4 mice. It is noteworthy that increased mRNA levels of SOCS‐3
and IL‐10 in the MCMV‐infected eyes of MAIDS‐10 mice preceded the decrease in IL‐17 mRNA
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levels seen in the eyes of these animals during retinitis development (Fig 4.6A), suggesting that
SOCS‐3 and/or IL‐10 contribute to the downregulation of IL‐17 during ocular MCMV infection.

Figure 4.9. SOCS‐1, SOCS‐3, and IL‐10 mRNA levels in MCMV‐infected eyes of MAIDS‐4 versus
MCMV‐infected eyes of MAIDS‐10 mice. (A) SOCS‐1 mRNA levels, (B) SOCS‐3 mRNA levels, and
(C) IL‐10 mRNA levels of MCMV‐infected eyes of MAIDS‐4 mice (dashed line) versus MCMV‐
infected eyes of MAIDS‐10 mice (solid line) collected at 3, 6, or 10 days after subretinal MCMV
infection (n = 5). Levels (fold‐change) of SOCS‐1 mRNA, SOCS‐3 mRNA, and IL‐10 mRNA were
determined by quantitative RT‐PCR assay. Bars = Standard Error of the Mean of 2 independent
experiments. Asterisks indicate statistical significance.
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4.2.9 Effect of systemic MCMV infection on IL‐17 mRNA and protein levels in whole splenic
cells and splenic CD4+ T cells of wildtype mice and IL‐10 ‐/‐ mice without MAIDS
Because we demonstrated that IL‐10 mRNA levels were upregulated in whole splenic
cells of MAIDS animals during the evolution of immunosuppression (Fig. 4.8C) as well as in the
eyes of retinitis‐susceptible MAIDS animals following subretinal MCMV infection (Fig. 4.9C) and
that the increase in IL‐10 mRNA is correlated with the decrease in IL‐17 mRNA observed in CD4+
T cells, we investigated whether knockout of IL‐10 would restore IL‐17 levels. Wild‐type mice
without MAIDS and IL‐10 ‐/‐ mice without MAIDS were systemically infected with a sublethal
dose of MCMV. Six days p.i., whole splenic cells and splenic CD4+ T cells were collected and
analyzed for IL‐17 mRNA and protein levels by real‐time RT‐PCR assay and ELISA, respectively.
Systemic MCMV infection of wild‐type mice resulted in a significant (p ≤ 0.03) decrease in IL‐17
mRNA levels (Fig. 4.10A) confirming our previous findings (Fig 4.7A). However, while IL‐17
mRNA levels were dampened in splenic cells of systemically infected IL‐10 ‐/‐ mice when com‐
pared to mock‐infected controls (Fig. 4.10A), IL‐17 protein levels were significantly (p ≤ 0.05)
increased in whole splenic cells of these mice [12.28± 7.7 pg of IL‐17 per gram of spleen (wet
weight)] when compared to systemically infected wild‐type mice [4.47± 3.5 pg of IL‐17 per gram
of spleen (wet weight)] (Fig. 4.10B). The production of IL‐17 mRNA in splenic CD4+ T cells was
significantly (p ≤ 0.03) reduced in both animal groups (Fig. 4.10C). However, IL‐17 mRNA levels
were moderately increased, showing ~2‐fold higher levels of production in systemically infected
IL‐10 ‐/‐ animals (Fig. 4.10D). These results suggest that IL‐10 knockout partially restored IL‐17
levels during systemic MCMV infection.
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Figure 4.10. IL‐17 mRNA and protein levels in whole splenic cells and splenic CD4+ T cells of
wild‐type mice and IL‐10 ‐/‐ mice following systemic MCMV infection. Comparison of IL‐17
mRNA levels of (A) whole splenic cells, (C) and (D) splenic CD4+ T cells collected from wild‐type
mice (n = 5) and IL‐10 ‐/‐ mice (n = 5) at 6 days following i.p. MCMV infection. Levels (fold‐
change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = Standard Error of
the Mean of 2 independent experiments. Comparison of IL‐17 protein levels of (B) whole
splenic cells collected from wild‐type mice (n = 5) and IL‐10 ‐/‐ mice (n = 5) at 10 days following
i.p. MCMV infection. Protein levels were determined by ELISA. Bars = Standard Error of the
Mean of 2 independent experiments. Asterisks indicate statistical significance.
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4.2.10 L‐17 mRNA and protein levels in whole splenic cells and eyes of wildtype MAIDS‐8 mice
and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV inoculation
Since we demonstrated that systemic MCMV infection of IL‐10 ‐/‐ mice without MAIDS
resulted in a partial restoration of IL‐17 mRNA and protein levels, we next wanted to determine
whether subretinal MCMV infection of retinitis‐susceptible IL‐10 ‐/‐ MAIDS‐8 mice also resulted
in partial recovery of IL‐17 mRNA and protein levels. Whole spleens and eyes were collected
from wild‐type MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 mice on day 10 after subretinal MCMV in‐
oculation and analyzed for IL‐17 mRNA and protein levels by real‐time RT‐PCR assay and ELISA,
respectively. Results are shown in Figure 4.11. While IL‐17 mRNA levels did not increase in ei‐
ther whole splenic cells or whole eyes of IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV in‐
oculation (Fig. 4.11A and 4.11B), IL‐17 protein levels were consistently elevated, although not
significantly, in both splenic cells and eyes of the IL‐10 ‐/‐ MAIDS‐8 animals (Fig. 4.11C and
4.11D). Ocular tissues collected from IL‐10 ‐/‐ MAIDS‐8 mice and analyzed for IL‐17 protein via
immunohistochemistry exhibited an enhancement in IL‐17 protein production when compared
to MCMV‐infected eyes of wild‐type MAIDS‐8 mice (Fig. 4.12), although both groups remained
equally susceptible to MCMV retinitis (85% frequency of retinitis, n = 7 mice/group). As ob‐
served during systemic MCMV infection, these results suggest that partial restoration of IL‐17
was not sufficient to protect MAIDS mice against MCMV retinitis.
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Figure 4.11. IL‐17 mRNA and protein levels in whole splenic cells and MCMV‐infected eyes of
wild‐type MAIDS‐8 and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection. Com‐
parison of IL‐17 mRNA levels in (A) whole splenic cells and (B) MCMV‐infected eyes of groups of
wild‐type MAIDS‐8 mice (n = 10) and IL‐10 ‐/‐ MAIDS‐8 mice (n = 10) at 10 days after subretinal
MCMV infection. Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR
assay. Bars = Standard Error of the Mean of 1 experiment. Comparison of IL‐17 protein levels in
(C) whole splenic cells and (D) MCMV‐infected eyes of groups of wild‐type MAIDS‐8 mice (n =
10) and IL‐10 ‐/‐ MAIDS‐8 mice (n = 10) at 10 days after subretinal MCMV infection. Protein lev‐
els were determined by ELISA. Bars = Standard Error of the Mean of 1 experiment. All compari‐
sons showed no statistical significance.
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Figure 4.12. Detection of IL‐17 protein in MCMV‐infected eyes of wild‐type MAIDS‐8 mice and
IL‐10 ‐/‐ MAIDS‐8 mice. Detection of IL‐17 in cells of representative retinal tissue sections col‐
lected from eyes of wild‐type MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 mice at 10 days after
subretinal MCMV infection or mock infection. Formalin‐fixed cytosections were reacted with
anti‐IL‐17 antibody (red) or an isotype‐matched normal antibody (control). Nuclei were coun‐
terstained with DAPI (blue) (200X).
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5
5.1

DISCUSSION, FUTURE DIRECTIONS, AND SIGNIFICANCE
Aim 1: Increased CD4+ T cell cytokines IL‐4 or IL‐10 dowregulate cellular immunity to
increase susceptibility to experimental MCMV retinitis in mice with MAIDS
Since its appearance as a major cause of vision loss and blindness within the United States

nearly 30 years ago, AIDS‐related HCMV retinitis has become well characterized clinically and
histologically (Dix and Cousins, 2004a; Holland, 1996). Despite many years of extensive clinical
and laboratory investigation, however, a number of basic issues related to the virology, immu‐
nology, and pathogenesis of this sight‐threatening disease within the unique immunosuppres‐
sive environment of HIV infection and disease remain unresolved. Among these is a crisp and
comprehensive understanding of the basic immunological changes that take place during retro‐
virus‐induced immunosuppression, especially those involved during loss of cellular immunity.
Toward this end, we previously used our MAIDS model of MCMV retinitis to show that the per‐
forin‐mediated cytotoxic pathway is more important than the Fas/FasL‐mediated cytotoxic
pathway in protection against MAIDS‐related MCMV retinitis (Dix et al., 2003a). We (Dix et al.,
2003a), and others (Loh et al., 2005), showed that loss of the perforin cytotoxic pathway results
in an increased susceptibility to MCMV‐induced disease, including retinitis. Resistance to
MCMV‐related disease, however, could be restored by immunotherapy with the Th1 cytokine
IL‐2 (Dix et al., 1997b), a cytokine that has robust effects on cytotoxic T cell and natural killer
(NK) cell functions (Smith, 1988). Unanswered in these investigations, however, was an under‐
standing of the precise mechanism(s) by which the perforin cytotoxic pathway is diminished
during MAIDS in favor of the Fas/FasL cytotoxic pathway. These findings, coupled with the fact
that progression of MAIDS is also associated with a prominent shift in cytokine production by
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CD4+ T cells from a Th1 profile to a Th2 profile (Dix and Cousins, 2004a) (Fig. 3.1) as seen during
AIDS (Clerici and Shearer, 1993), lead to the attractive hypothesis that IL‐4 or IL‐10, both Th2
cytokines that have been shown to be involved in downregulation of cellular immunity (Aung
and Graham, 2000; Baschuk et al., 2007; Dix et al., 2003a; Kienzle et al., 2002; Kienzle et al.,
2005), play key roles in the pathogenesis of MAIDS‐related MCMV retinitis.
Results reported herein suggest that this is not the case, and our hypothesis is incorrect.
In fact, MCMV‐infected eyes of mice with MAIDS deficient in systemic IL‐4 or IL‐10 displayed a
frequency of retinitis, a severity of retinitis, and intraocular amounts of virus equivalent to
those found in MCMV‐infected eyes of wild‐type mice with MAIDS.
That IL‐4 or IL‐10 should play a pivotal role in loss of cellular immunity during the patho‐
genesis of MAIDS‐related MCMV retinitis was a reasonable prediction. In addition to studies
that have shown that increased IL‐4 or IL‐10 production during HIV infection results in de‐
creased cytotoxic CD8+ T‐cell activity against many viruses including HCMV (Elrefaei et al.,
2006; Elrefaei et al., 2007; Erard et al., 1994; Erard et al., 1993), numerous in vitro and in vivo
studies have also noted an association between elevated levels of the Th2 cytokine IL‐4 and de‐
creased CD8+ T‐cell‐mediated cytotoxicity, all associated with an increase in FasL expression
and a concomitant decrease in perforin and granzyme B expression. For example, Kienzle and
colleagues (Kienzle et al., 2002; Kienzle et al., 2005) demonstrated that incubation of naïve
mouse CD8+ T cells to high concentrations of IL‐4 resulted in a population of T cells with signifi‐
cantly lower expression of CD8 and reduced cytotoxic ability. Aung and coworkers (Aung and
Graham, 2000) infected mice with an IL‐4‐expressing respiratory RSV recombinant and ob‐
served a subsequent increase in expression of FasL on CD4+ and CD8+ T cells coupled with al‐
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teration of the mechanism of CD8+ T‐cell cytotoxicity from a perforin‐mediated pathway to a
favored Fas/FasL‐mediated pathway. Moreover, systemic treatment of mice with anti‐IL‐4 anti‐
body resulted in decreased morbidity following challenge with wild‐type RSV due to an en‐
hanced CD8+ cytotoxic response that lead to more effective virus clearance (Aung and Graham,
2000). Similar findings were reported by Jackson and colleagues (Jackson et al., 2001) for
mousepox virus infection. These workers observed suppressed CD8+ T‐cell cytotoxicity as well
as suppressed NK‐cell cytotoxicity in mice infected with an IL‐4‐expressing mousepox virus, out‐
comes that resulted in increased virus‐induced mortality.
Despite this convincing body of evidence, we did not observe increased resistance to
MCMV retinitis in mice with MAIDS in the absence of functional IL‐4 or IL‐10 production as hy‐
pothesized. Without functional IL‐4 or IL‐10, two Th2 cytokines thought to dampen cellular im‐
munity during retrovirus‐induced immunosuppression (Elrefaei et al., 2006; Elrefaei et al., 2007;
Erard et al., 1994; Erard et al., 1993; Furukawa et al., 2008), we predicted a resurgence in CD8+
T‐cell cytotoxicity that would provide protection against onset and progression of MCMV‐
induced retinal disease, possibly through stimulation of the perforin cytotoxic pathway associ‐
ated with a concomitant decline in the Fas/FasL cytotoxic pathway. Surprisingly, this was not
the case. In fact, loss of IL‐4 or IL‐10 during MAIDS resulted in no significant change in splenic
mRNA levels for perforin or granzyme B, two key molecules involved in the perforin cytotoxic
pathway, when compared with wild‐type mice with MAIDS. More importantly, an increase in
splenic mRNA levels for FasL was observed following loss of either IL‐4 or IL‐10 during MAIDS
when compared with wild‐type mice with MAIDS. One explanation for these unexpected results
is that while IL‐4 or IL‐10 may work individually to suppress cellular immunity during MAIDS,
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they also function collectively toward this end. Our findings suggest that loss of IL‐4 or IL‐10
during MAIDS is an independent event that fails to affect production of the other Th2 cytokine.
In fact, whole splenic cells from IL‐4 ‐/‐ MAIDS mice exhibited increased IL‐10 protein levels and
whole splenic cells from IL‐10 ‐/‐ MAIDS mice exhibited equivalent IL‐4 protein levels to wild‐
type MAIDS mice, which potentially explains why these individual knockout MAIDS animals re‐
mained susceptible to retinitis. Thus, loss of one of these Th2 cytokines is not sufficient to re‐
duce the frequency or severity of MAIDS‐related MCMV retinitis in these animals.
Another possible explanation for our unexpected findings may be that neither IL‐4 nor IL‐
10 play a role in governing susceptibility to MCMV retinitis. It is noteworthy that more recent
findings from other laboratories have suggested that IL‐4 can indeed support development of
cytotoxic T cells when incubated with highly purified primary T cells collected from lymph nodes
of BALB/c mice (Miller et al., 1990; Trenn et al., 1988). Studies conducted by Bachmann and
coworkers (Bachmann et al., 1995) also demonstrated that IL‐4 ‐/‐ C57BL/6 mice, when com‐
pared with wild‐type C57BL/6 mice, failed to exhibit changes in cytotoxic T‐cell responses when
infected with lymphocytic choriomeningitis virus (LCMV) or vaccinia virus. These animals were
also able to clear virus as a result of an effective cytotoxic T‐cell response. Additional studies
conducted by Mo and colleagues (Mo et al., 1997) noted that CD8+ T cells collected from IL‐4 ‐
/‐ 129/J mice and wild‐type 129/J mice exhibited equivalent cytotoxic activity against Sendai
virus infection. Similarly, IL‐10 has also been found to promote T cell development as well as
CD8+ T cell cytotoxicity (Chen and Zlotnik, 1991; MacNeil et al., 1990; Santin et al., 2000). In
fact, human pappillomavirus‐specific CD8+ T cells isolated from cervical cancer patients that
were incubated with IL‐10 + IL‐2 exhibited increased cytotoxicity over that observed in CD8+ T
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cells incubated with IL‐2 alone (Santin et al., 2000). This increase CD8+ T cell cytotoxicity was
correlated with increased perforin levels in the IL‐10 + IL‐2‐treated CD8+ T cells (Santin et al.,
2000). While it is important to recognize that none of these studies investigated IL‐4 or IL‐10
and cellular immunity in the context of retrovirus‐induced immunosuppression, these data indi‐
cate that perhaps neither IL‐4 nor IL‐10 decrease CD8+ T cell cytotoxicity to increase susceptibil‐
ity to MCMV retinitis.
In summary, we show herein that mice with MAIDS deficient in either IL‐4 or IL‐10 do not
develop resistance to MCMV retinitis as measured by amounts of intraocular infectious virus,
frequency of retinitis, and severity of retinitis. Our findings therefore disprove our initial work‐
ing hypothesis that IL‐4 or IL‐10 are key Th2 cytokines that promote increased susceptibility to
MAIDS‐related MCMV retinitis by dampening of cellular immunity, possibly by favoring the
Fas/FasL cytotoxic pathway over the perforin cytotoxic pathway. However, IL‐4 and IL‐10 may
work collectively with each other as well as with other host factors to create the unique in‐
traocular environment that allows for pathogenesis of MCMV retinitis.
5.1.1 Future directions
Future studies should address whether IL‐4 and IL‐10 work in a synergistic manner to
govern susceptibility to MCMV‐related retinitis during MAIDS. One experimental approach to
test this hypothesis would be to perform parallel studies using mice with MAIDS that suffer sys‐
temic loss in both IL‐4 and IL‐10 production. Unfortunately, double knockout mice exist only on
a BALB/c background (Jackson Laboratory, Strain 004291), and MAIDS cannot be induced in
BALB/c mice (Hartley et al., 1989). Alternatively, we could reduce systemic levels of both IL‐4
and IL‐10 in mice with MAIDS using an antibody approach to neutralize their functions. How‐
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ever, studies to reduce systemic levels of only IL‐4 in mice with MAIDS using anti‐IL‐4 antibody
proved to be ineffective, resulting in only ~50% reduction in splenic levels of IL‐4 mRNA and
protein (Fig. 3.2). Lastly, future studies of CD8+ T cell cytotoxicity utilizing flow cytometry‐
based killing assays would be a nice addition to this study in order to show that CD8+ T cell‐
mediated cytotoxic activities in the IL‐4 ‐/‐ MAIDS mice and the IL‐10 ‐/‐ MAIDS mice are
equivalent to the CD8+ T cell‐mediated cytotoxic activities seen in wild‐type MAIDS mice and
that this loss in cell‐mediated cytotoxicity is correlated with increased FasL mRNA expression in
whole splenic cells of the knockout MAIDS animals.

5.2

Aim 2: Increased production of IL‐17 from CD4+ Th17 cell contributes to the pathogene‐
sis of experimental MCMV retinitis in mice with MAIDS
The aims of the present study were to determine the fate of IL‐17 during HIV infection,

and to determine whether IL‐17 contributes to the pathogenesis of AIDS‐related HCMV retinitis
through the use of a clinically relevant mouse model of MAIDS‐related MCMV retinitis.
Whereas IL‐17 expression was detected within the spleen and eyes of healthy mice, IL‐17 mRNA
and protein were increased systemically during MAIDS progression when compared to healthy
mice. However, MCMV‐infected eyes of retinitis‐susceptible MAIDS‐10 mice, but not MCMV‐
infected eyes of retinitis‐resistant MAIDS‐4 mice, exhibited a significant decrease in IL‐17 mRNA
expression and dampened IL‐17 protein levels. IL‐17 mRNA was also decreased in whole splenic
cells as well as in splenic CD4+ T cells of healthy mice and MAIDS animals upon systemic MCMV
infection. This decrease was associated with increased levels of SOCS‐3 and IL‐10 mRNAs during

106

MCMV infection. However, knockout of IL‐10 in MAIDS mice only partially restored IL‐17 levels
and failed to protect mice against MCMV retinitis.

5.2.1 IL‐17 production in splenic cells and eyes of C57BL/6 mice during health
IL‐17 was detected at low levels in the spleens of healthy mice, an observation consis‐
tent with that of Brenchley and coworkers (Brenchley et al., 2008) who detected low levels of
IL‐17‐expressing CD4+ T cells in the peripheral blood of healthy human patients. IL‐17 was also
detected in cells of the neurosensory retina and the photoreceptor layer of healthy mice, but IL‐
17 production in the eye was lower than that in the spleen. Further investigation determined
that both cell types that comprise the photoreceptor layer, rod cells and cone cells, constitu‐
tively express IL‐17 during health. To our knowledge, ours is the first study to identify resident
IL‐17‐expressing cells within the ocular compartment of healthy mice. We postulate that in ad‐
dition to retinal photoreceptors cells, retinal pericytes and/or microglia also produce IL‐17 in
the healthy mouse eye due to their distribution within the neurosensory retina and their ability
to secrete inflammatory cytokines (Chen et al., 2002; Crane and Liversidge, 2008; Guillemin and
Brew, 2004). Future experiments should be focused on determining the cellular source of IL‐17
production in the neurosensory retina of healthy mice.

5.2.2 IL‐17 production in splenic cells and eyes of C57BL/6 mice during progression of MAIDS
Previous studies on IL‐17 production during HIV/AIDS remain discordant (Brenchley et
al., 2008; Maek et al., 2007; Yue et al., 2008). Our findings using mice with MAIDS to determine
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the fate of IL‐17 during the progression of retrovirus‐induced immunosuppression agreed with
previous studies (Maek et al., 2007; Yue et al., 2008) showing IL‐17 production was increased in
patients during HIV infection. We observed a significant increase in IL‐17 mRNA and protein
levels in whole splenic cell populations as well as in mRNA in whole eyes when compared to
healthy age‐matched controls. However, unlike whole splenic cells, MAIDS progression was also
associated with a concomitant decrease in IL‐17 mRNA levels in splenic CD4+ T cells, a finding
that was in agreement with Brenchley and coworkers (Brenchley et al., 2008) observations in
HIV‐infected individuals. Other known cellular sources of IL‐17, splenic macrophages and
splenic Gr‐1‐expressing cells (neutrophils), contributed little to the overall IL‐17 mRNA levels
observed during MAIDS progression suggesting that there is not one sole source of IL‐17 pro‐
duction by these animals. Thus, CD4+ T cells, macrophages, and Gr‐1‐expressing cells (neutro‐
phils) in combination with other known sources of IL‐17 including natural killer T cells (NKTs),
CD8+ T cells, and gamma‐delta (γδ) T cells (Gaffen, 2009; Iwakura et al., 2011; Rachitskaya et al.,
2008) might all collectively contribute to the overall increase of IL‐17 observed during MAIDS.
The contributions of each of the other known cellular sources of IL‐17, including CD8+ T cells,
NKT cells, and γδ T cells, to the increased levels of IL‐17 observed in whole splenic cells of
MAIDS mice during retrovirus‐induced immunosuppression progression should be assessed in
future studies.

5.2.3 IL‐17 production and susceptibility to MCMV retinitis during MAIDS
Intraocular IL‐17 production has been associated with uveitis, an inflammatory disease
of the retina and uvea. Disease etiology is autoimmune in nature, with patients exhibiting im‐
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mune responses to ocular antigens including retinal arrestin and interphotoreceptor retinoid‐
binding protein (Caspi, 2010). EAU in mice has defined with some precision the effector cells
involved in retinal and uveal tissue destruction during disease pathogenesis (Caspi, 2010; Luger
and Caspi, 2008; Luger et al., 2008). Originally thought to be solely a Th1‐mediated disease,
uveitis is also induced through the actions of Th17 cells and IL‐17 secretion (Caspi, 2010; Luger
and Caspi, 2008; Luger et al., 2008). Neutralization of IL‐17 through passive transfer of anti‐IL‐
17 antibody has been shown to mitigate EAU severity significantly (Amadi‐Obi et al., 2007;
Luger et al., 2008; Peng et al., 2007). Conversely, adoptive transfer of retinal antigen‐specific
Th17 cells has been shown to induce EAU development in naïve mice (Luger et al., 2008; Peng
et al., 2007).
Because IL‐17 is involved in uveitis pathogenesis, we sought to determine whether the
increase in IL‐17 levels seen in mice with MAIDS played a role in susceptibility to MCMV retini‐
tis. Whereas MAIDS‐4 mice resistant to retinitis did not exhibit changes in IL‐17 mRNA levels
following subretinal MCMV inoculation when compared to mock‐infected controls, MCMV‐
infected eyes of MAIDS‐10 mice susceptible to retinitis exhibited a significant decrease in IL‐17
mRNA levels. Additionally, ocular IL‐17 protein levels and patterns of IL‐17 immunohistochemi‐
cal staining were dampened in MCMV‐infected eyes of these retinitis‐susceptible animals when
compared to mock‐infected eyes. We therefore conclude that IL‐17 plays no direct role in in‐
creased susceptibility to MCMV retinitis during MAIDS. It is possible, however, that IL‐17 may
act indirectly to increase susceptibility to MCMV retinitis or may play a protective role in MCMV
retinitis development in MAIDS mice.
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5.2.4 IL‐17 production in splenic CD4+ T cells of healthy mice and MAIDS mice following sys‐
temic MCMV infection
The surprising observation of significantly reduced IL‐17 mRNA and dampened protein
levels during ocular MCMV infection of MAIDS‐10 mice led us to investigate whether MCMV
actually downregulated IL‐17 production from CD4+ T cells systemically. In agreement with this
hypothesis was our finding that systemic MCMV infection resulted in a significant reduction of
IL‐17 mRNA levels in whole splenic cells and splenic CD4+ T cells from groups of healthy mice,
MAIDS‐4 mice, and MAIDS‐10 mice. Moreover, experiments using UV‐inactivated virus sug‐
gested that active MCMV infection was not an absolute requirement for reduction of IL‐17
mRNA in CD4+ T cells, although productive MCMV replication did result in a more profound de‐
crease in IL‐17 mRNA levels. Taken together, these results suggest that a structural MCMV pro‐
tein(s) as well as one or more virus‐induced proteins during virus replication might work in con‐
cert to contribute to the downregulation of IL‐17 through the upregulation of IL‐10 and SOCS‐3
(Fig. 5.1).
It is interesting to note that a structural protein of HCMV, the pp65 tegument protein,
has been shown to alter the host immune response early during infection by blocking the inter‐
feron response and inhibiting the activity of NK cells through direct interaction with its receptor
(Arnon et al., 2005; Kalejta, 2008; Miller‐Kittrell and Sparer, 2009). Since MCMV encodes a pp65
homolog, M83/84 (Cranmer et al., 1996; Kattenhorn et al., 2004), it is possible that the M83/84
tegument protein of MCMV might also serve to downregulate IL‐17 production in MCMV‐
infected cells. The action of these tegument proteins leads to decreased T cell activation and
ultimately a decreased immune response that favors viral replication and persistence. It is pos‐
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sible then that during MCMV infection, the actions of tegument proteins indirectly leads to the
decreased production of inflammatory cytokines including IL‐17 from CD4+ T cells, macro‐
phages, and neutrophils (Gr‐1‐expressing cells).
Structural HCMV glycoproteins also exhibit immune evasion properties. MCMV gp34,
gp40, and gp48 are functional homologs of HCMV glycoproteins encoded by viral genes US2,
US3, and US11, respectively (Kavanagh et al., 2001). These MCMV viral glycoproteins decrease
MHC I protein expression on virus‐infected cells (Kattenhorn et al., 2004; Kavanagh et al., 2001;
Loewendorf and Benedict, 2010; Loewendorf et al., 2011; Mocarski, 2002; Wagner et al., 2002),
leading to decreased CD4+ T cell and CD8+ T cell activation. In addition, the MCMV m155 pro‐
tein inhibits expression of the CD4+ T cell and CD8+ T cell stimulator protein CD40 in virus‐
infected monocytes/macrophages as well as in virus‐infected dendritic cells (Elgueta et al.,
2009; Loewendorf et al., 2011; Ma and Clark, 2009). The action of these viral glycoproteins to
decease the activation of CD4+ T cells might account for the reduction in IL‐17 production from
CD4+ T cells that was observed during MCMV infection of healthy mice and mice with MAIDS.
Future experiments should be done to investigate the exact role of these viral proteins in IL‐17
downregulation during systemic and ocular MCMV infection. Selective overexpression or
knockdown of MCMV immunoregulatory tegument proteins m83/84 and/or MCMV immune
evasion viral glycoproteins utilizing a bacterial artificial chromosome (BAC) system would reveal
their direct involvement in downregulating IL‐17 during systemic MCMV infection and whether
the downregulation of IL‐17 by MCMV is directly correlated with increased IL‐10 and SOCS‐3
levels.
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In addition to MCMV viral tegument and glycoproteins contributing to the downregula‐
tion in IL‐17 during infection, cytokine secretion from infected, activated macrophages may also
contribute to the downregulation of IL‐17 during systemic infection of mice with both actively
replicating MCMV as well as UV‐inactivated MCMV. Both HCMV and MCMV infection induce
the production of immunosuppressive IL‐10 (Humphreys et al., 2007; Redpath et al., 1999) in
infected macrophages as well as in CD4+ T cells. We confirmed the upregulation of IL‐10 in
splenic CD4+ T cells of MAIDS‐10 mice during MCMV infection (data not shown). In addition, IL‐
10 secretion from anti‐inflammatory M2 macrophages promotes wound healing as well as an‐
giogenesis, which consequently leads to the reduction of pro‐inflammatory cytokines (Cassetta
et al., 2011; Gordon, 2003; Mosser and Edwards, 2008; Sunderkotter et al., 1994). We believe
that an upregulation of IL‐10 from M2 macrophages as well as CD4+ T cells during MCMV infec‐
tion as well as during UV‐inactivated MCMV infection may potentially contribute to the down‐
regulation of IL‐17 we observed in both our healthy and MAIDS mice. However, MCMV and
HCMV have been also noted to induce the secretion of pro‐inflammatory cytokines from
macrophages including TNF‐α, IL‐1β, and IL‐6 during infection (Iwamoto et al., 1990; Pulliam et
al., 1995; Smith et al., 1992; Vliegen et al., 2004). Pro‐inflammatory M1 macrophage cytokines
have been associated with increased IL‐17 production and vise versa (Jovanovic et al., 1998;
Sutton et al., 2006). Based on our results from these studies, we believe that acute MCMV in‐
fection leads to the induction of M2 macrophages as well as CD4+ T cells that secrete IL‐10,
which ultimately contributes to the downregulation in IL‐17 that we observed in whole splenic
cells as well as splenic CD4+ T cells of systemically infected healthy and MAIDS mice.
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5.2.5 Proposed mechanism of IL‐17 downregulation during MCMV infection
The observation that IL‐17 was decreased in CD4+ T cells during MAIDS progression as
well as during ocular and systemic infection of retinitis‐susceptible MAIDS animals led us to in‐
vestigate possible mechanisms by which retrovirus‐induced immunosuppression might down‐
regulate IL‐17 production by CD4+ T cells. Recent studies have implicated both SOCS‐3 and IL‐10
as negative regulators of IL‐17 secretion (Chaudhry et al., 2011; Gu et al., 2008; Huber et al.,
2011). It is therefore possible that increases in one or both of these proteins would cause the
IL‐17 mRNA decrease observed by us in CD4+ T cells during MAIDS progression. SOCS‐3 is in‐
duced by cytokine signaling (Yoshimura et al., 2007) and negatively regulates Th17 cell differen‐
tiation by suppressing STAT3 activation of IL‐6 and IL‐23 receptors on Th17 cells (Chen et al.,
2006; Yoshimura et al., 2007). Additionally, SOCS‐3 levels are increased during HIV infection
(Akhtar and Benveniste, 2011; Akhtar et al., 2010). We have shown that SOCS‐3 mRNA levels
were significantly increased during retrovirus‐induced immunosuppression, with mRNA levels
peaking in MAIDS‐10 mice when most susceptible to MCMV retinitis (Dix and Cousins, 2004a;
Dix et al., 1994). Importantly, the increase in SOCS‐3 mRNA levels correlated with the decrease
in IL‐17 mRNA levels seen in CD4+ T cells during MAIDS progression, suggesting a potential ex‐
planation for the observed downregulation in IL‐17 mRNA from CD4+ T cells during MAIDS pro‐
gression.
While little is currently known about the potential induction of SOCS‐3 or SOCS‐1 during
MCMV infection, a number of viruses including influenza, respiratory syncytial virus (RSV), HIV,
and HSV‐1 exploit SOCS proteins, activating them in order to evade the host cell immune re‐
sponse (Akhtar and Benveniste, 2011; Frey et al., 2009; Yokota et al., 2005). We propose that
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MCMV acts in a similar manner to upregulate SOCS‐1 and SOCS‐3 proteins. While we observed
increases in both SOCS‐1 and SOCS‐3 mRNA levels in the MCMV‐infected eyes of MAIDS‐4 and
MAIDS‐10 mice, levels were far higher in the MCMV‐infected eyes of MAIDS‐10 mice that were
susceptible to retinitis. Importantly, the increase in ocular SOCS‐3 mRNA levels preceded the
decrease in IL‐17 mRNA seen in MCMV‐infected eyes of MAIDS‐10 mice. In addition, the in‐
crease in SOCS‐3 mRNA on day 6 was approximately 10‐fold higher than the SOCS‐1 mRNA lev‐
els we observed in the MCMV‐infected eyes of MAIDS‐10 mice. These results indicate to us that
while positive regulator of Th17 cell differentiation SOCS‐1 was significantly increased during
the development of MCMV retinitis in MAIDS‐10 mice, these mRNA levels were not high
enough to overcome the dramatic increase in mRNA that we observed in the Th17 cell negative
regulator SOCS‐3. Protein levels for both SOS‐1 and SOCS‐3 determined by Dr Hsin Chein in our
laboratory (unpublished data) mirrored our mRNA results, where both SOCS‐1 and SOCS‐3 pro‐
tein levels were significantly increased in the MCMV‐infected eyes of MAIDS‐10 mice when
compared to MCMV‐infected eyes of MAIDS‐4 mice. However, protein levels in MCMV‐infected
eyes of both MAIDS‐4 and MAIDS‐10 mice peaked on day 10. The highest levels of SOCS‐3 pro‐
tein on day 10 correlated with the significant downregulation of IL‐17 we observed the in
MCMV‐infected eyes of MAIDS‐10 mice. This suggests that in addition to the action of its viral
tegument proteins and glycoproteins, MCMV may also upregulate SOCS‐3 for efficient viral rep‐
lication or for evasion of the host immune response, which, in turn, results in the downregula‐
tion of IL‐17.
IL‐10 is an anti‐inflammatory cytokine secreted by numerous immune cells, and it is able
to regulate IL‐17 secretion by binding to its receptor on Th17 cells (Chaudhry et al., 2011;
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Couper et al., 2008; Huber et al., 2011). In our study, we demonstrated that IL‐10 mRNA levels
were significantly increased during MAIDS progression, and peaked at 10 weeks after retrovi‐
rus‐induced immunosuppression when animals were susceptible to MCMV retinitis (Dix and
Cousins, 2004a; Dix et al., 1994). Similar to SOCS‐3, the increase in IL‐10 mRNA levels correlated
with the decrease in IL‐17 mRNA levels seen in CD4+ T cells during MAIDS progression.
Systemic MCMV infection also induces expression of IL‐10 in both CD4+ T cells as well as
in MCMV‐infected macrophages (Humphreys et al., 2007; Redpath et al., 1999). Increased pro‐
duction of IL‐10 during MCMV infection leads to reduction of MHC class II on virus‐infected cells
and subsequently a decreased host response (Redpath et al., 1999). In agreement with these
studies, we observed a significant increase in IL‐10 mRNA levels in MCMV‐infected eyes of
MAIDS‐10 mice that were susceptible to MCMV retinitis. As IL‐10 mRNA levels increased during
MCMV retinitis development, IL‐17 mRNA levels decreased. It is therefore possible that MCMV
infection orchestrates the downregulation of IL‐17 through the induction of IL‐10 along with
SOCS‐3.
Although systemic MCMV infection of IL‐10 ‐/‐ mice without MAIDS resulted in an in‐
crease in IL‐17 mRNA and protein in whole splenic cells and an increase in IL‐17 mRNA expres‐
sion levels in CD4+ T cells, and subretinal MCMV infection of MAIDS‐8 IL‐10 ‐/‐ mice led to ele‐
vated levels of IL‐17 protein in whole splenic cells and MCMV‐infected eyes, this partial recov‐
ery was not sufficient to protect MAIDS‐8 mice against MCMV retinitis development. These re‐
sults suggest that knockout of IL‐10 results only in a partial restoration of IL‐17 expression lev‐
els. Thus, other proteins, such as SOCS‐3 and/or MCMV viral proteins, contribute to the down‐
regulation of IL‐17 during MCMV infection.
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In conclusion, we have demonstrated that IL‐17 plays no direct role in the pathogenesis
of MAIDS‐related MCMV retinitis. Remarkably, however, systemic MCMV infection of mice with
MAIDS resulted in the downregulation of IL‐17 production from CD4+ T cells, possibly through
the actions of MCMV viral proteins and/or the upregulation of SOCS‐3 and IL‐10 mRNA produc‐
tion (Fig. 5.1) during infection. SOCS‐3 and IL‐10 may work in a synergistic manner to downregu‐
late IL‐17 from CD4+ T cells, although the direct role of SOCS‐3 in downregulation of IL‐17 dur‐
ing MCMV infection remains unclear. Lastly, while partial restoration of IL‐17 through knockout
of IL‐10 did not reduce the frequency and/or severity of MCMV retinitis in MAIDS animals, it
remains to be determined whether full restoration of IL‐17 from Th17 cells during MAIDS plays
a protective role in resistance to MCMV retinitis.
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Figure 5.1. Proposed mechanism for downregulation of IL‐17 in Th17 cells by MCMV. MCMV
infection stimulates IL‐10 production during health and retrovirus‐induced immunosuppression.
IL‐10 binds to its receptor on Th17 cells that induces activation of Janus kinase‐1 (Jak1) and ty‐
rosine kinase‐2 (Tyk2) that leads to the phosphorylation of signal transducer and activator of
transcription‐3 (STAT‐3). Phosphorylated STAT‐3 translocates to the nucleus where it upregu‐
lates SOCS‐3 transcription that results in an increase in SOCS‐3 protein intracellularly and ulti‐
mately inhibition of STAT‐3 phosphorylation at the IL‐6 and IL‐23 receptors on Th17 cells. This
inhibition culminates in decreased production of IL‐17 by Th17 cells. [Adapted from (Sabat et
al., 2010; Yoshimura et al., 2007)]
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5.2.6 Future directions
While the results obtained from this study indicated that IL‐17 does not play a direct
role in MCMV‐related retinitis pathogenesis, IL‐17 may play an indirect role in governing sus‐
ceptibility to MCMV retinitis development in MAIDS mice. For example, the progression of
MAIDS results in increased numbers of neutrophils and macrophages systemically (Mosier et
al., 1985), and it is possible that the increased systemic IL‐17 we observed during the progres‐
sion of retrovirus‐induced immunosuppression, from multiple cellular sources, leads to the ac‐
tivation of these neutrophils and macrophages (Annunziato et al., 2010; Iwakura et al., 2011;
Stockinger et al., 2007; Weaver et al., 2007). IL‐17‐activated macrophages and neutrophils in
MAIDS mice may then perfuse into the tissues, including the eyes of MAIDS animals. This influx
of activated macrophages and neutrophils into the eyes of MAIDS mice during subretinal
MCMV infection caused by elevated IL‐17 levels could thus contribute to retinitis development
through the production of pro‐inflammatory cytokines (i.e., TNF‐α) by these cells (Chien and
Dix, 2012; Dix and Cousins, 2004b). The use of IL‐17A ‐/‐ mice in future experiments, through a
collaboration with Dr. Chen Dong (Martin‐Orozco et al., 2009), would allow us to decipher the
exact role of IL‐17 during the development of MAIDS as well as during MCMV‐retinitis devel‐
opment in MAIDS animals.
On the other hand, because we observed decreased in IL‐17 levels during MCMV infec‐
tion of retinitis‐susceptible MAIDS‐10 mice, it is possible that IL‐17 is important in mitigating
rather than exacerbating MCMV‐related retinal disease development. Future studies should
investigate whether or not treatment of retinitis‐susceptible MAIDS mice with recombinant IL‐
17 prior to subretinal MCMV infection provides protection against MCMV‐related retinitis de‐
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velopment. However, ocular administration of recombinant IL‐17 of retinitis‐susceptible MAIDS
mice during subretinal MCMV infection may be necessary in order to determine the potential
protective properties of IL‐17 during MCMV retinitis development. Additionally, if knockdown
of the tegument proteins and/or the immune evasion viral glycoproteins leads to the upregula‐
tion of IL‐17 during infection, this would provide an alternative approach for us to determine
whether IL‐17 plays a protective role in MCMV retinitis pathogenesis.
Due to the current unavailability of IL‐17A ‐/‐ mice, we aimed to better decipher the role
of IL‐17 during MCMV retinitis development in MAIDS mice by altering an IL‐17 negative regula‐
tor in this current study, IL‐10, that was upregulated systemically during MAIDS progression as
well as in during ocular MCMV infection of retinitis‐susceptible MAIDS mice. Additionally,
SOCS‐3 was also upregulated in both whole splenic cells during the progression of MAIDS and in
MCMV‐infected eyes of MAIDS‐10 mice. We believe that the loss of SOCS‐3 would partially re‐
store IL‐17 levels in a similar fashion to what we observed in our IL‐10 ‐/‐ mice. However,
knockdown of SOCS‐3 in mice is lethal (Robb et al., 2005; Takahashi et al., 2003). SOCS‐3 condi‐
tional knockouts, mice devoid of SOCS‐3 protein production in particular tissues, could be util‐
ized, but mice lacking SOCS‐3 protein in the ocular tissues are not commercially available. Addi‐
tionally, SOCS‐3 antibody treatment could be utilized; however, when we utilized antibody
treatment to downregulate IL‐4 in our MAIDS animals, we only obtained a 50% reduction in IL‐4
protein (Aim 1, Fig. 3.2). Thus, SOCS‐3 antibody treatment of MAIDS mice does not present a
practical model to decipher the role of IL‐17 in MCMV‐related retinitis. We could also consider
developing mice that overexpress either SOCS‐3 or IL‐10 as well as both SOCS‐3 and IL‐10 in
ocular tissues in order to determine the degree to which each of these cytokines downregulates
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IL‐17 during infection. Based on our results from this study utilizing IL‐10 ‐/‐ MAIDS mice, we
believe that in addition to IL‐10, SOCS‐3 contributes to the downregulation of IL‐17 during
MCMV infection, and that the loss of both of SOCS‐3 and IL‐10 is essential for fully restoring IL‐
17 levels in Th17 cells during systemic and ocular MCMV infection.

5.3

Significance
Overall, the results from these studies furthers our basic understanding of the patho‐

genesis of AIDS‐related HCMV retinitis as well as our understanding of the immunobiology of
HCMV. Analysis of the host cell CD4+ T cell cytokines IL‐17, IL‐4, and IL‐10 during retrovirus‐
induced immunosuppression as well as during the development of retinal disease provide evi‐
dence for their collaborative involvement in disease development (IL‐4 and IL‐10) as well as
their potential protective capabilities (IL‐17). Further study of the mechanism of action of these
cytokines will help to direct the development of novel drug targets to manage existing HCMV
retinitis and/or prevent its development in HIV/AIDS patients.
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